

STIC-EIC1600/2900

256512

From: CRAIG RIGGS [craig.riggs@usace.gov]
 Sent: Thursday, April 03, 2008 3:23 PM
 To: STIC-EIC1600/2900
 Cc: NPL Feedback
 Subject: Database Search Request Serial Number 10566911

Requester: CRAIG RIGGS (P/1614)
 App Unit: GROUP ART UNIT 1614
 Fmg: ☒
 CTO: 3000
 PNL: 5654
 Mailbox Number:

Case serial number: 10566911
 Class / Subclass(es): 514/383
 Earliest Priority Expiry Date: 102(c)=3/04/2004, 102(a,e)=2/12/2003
 Former preferred for results: Patent
 Attachment: No.
 Search Topic Information:

This is a follow up to a search request posted yesterday for the same application. In more detail: Please search claim 1. Specifically, is there prior art that renders any 1 or more of the alternative members of the group of acrole derivatives of formula 1 (ie, formula 1 wherein A is O, R is CH₃, R' is H, etc etc: not-novel? Also, if no prior art can be found to render 1 or more of the alternative members of the group of acrole derivatives of formula 1 not novel, can you please provide the following analysis: 1. Do the acrole derivatives of formula 1 as provided in claim 1 have a common property or activity? AND 2. Do they share a common structure OR do they belong to a recognized class of chemical compounds in the art (in other words, can each member be substituted for the other to provide the same expected result)?

Special Instructions and Other Comments:

Thank you.

.....
 Description:
 Applicant Name:
 Date Received: 04/03/2008
 Date Completed:
 Section Tag:
 Print Time:

.....
 Type of Search:
 Class:
 Subclass: 514/383
 Keyword:
 Keyword 2:
 Keyword 3:

.....
 Search Report:
 Title:
 Abstract:
 Claims:
 Figures:
 Other:

=> file registry

FILE 'REGISTRY' ENTERED AT 14:24:28 ON 16 APR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

Uploading L15.str



```

chain nodes :
 7 8 9 10 11 12 22 23 24
ring nodes :
 1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
4-22 7-22 8-9 8-22 9-10 10-11 11-12 11-23 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
4-22 7-22 8-9 8-22 9-10 10-11 11-23 12-14
exact bonds :
11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 22:CLASS
23:CLASS 24:CLASS
25:CLASS
Generic attributes :
9:
Saturation          : Unsaturated


Element Count :
Node 8: Limited

```

10/566911

N,N1

Uploading L45.str



chain nodes :

7 8 9 10 11 12 21 22 24 27 30 31 36 38

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18

chain bonds :

4-27 7-27 8-9 8-27 9-10 10-11 11-12 11-21 12-14 12-38 27-36

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

4-27 8-9 8-27 9-10 11-21 12-38 27-36

exact bonds :

7-27 10-11 11-12 12-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

G1:[*1],[*2]

G2:H,CF3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS

22:CLASS 24:CLASS

25:CLASS 26:CLASS 27:Atom 30:CLASS 31:Atom 36:CLASS 38:CLASS

Generic attributes :

9:

Saturation : Unsaturated

27:

Saturation : Saturated

31:

Saturation : Unsaturated

Element Count :

Node 8: Limited

N,N2

C,C3


Node 9: Limited

C,C6

10/566911

Node 31: Limited
N,N3
C,C3

Uploading L59.str



chain nodes :
7 8 9 10 19 20 21 24 27 28 33 35
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
4-24 7-24 8-9 8-24 9-10 10-35 12-35 19-35 24-33
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
4-24 8-9 8-24 9-10 10-35 12-35 19-35 24-33
exact bonds :
7-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

G1:[*1],[*2]

G2:H,CF3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:Atom 20:Atom 21:Atom
22:CLASS 23:CLASS
24:Atom 27:CLASS 28:Atom 33:CLASS 35:CLASS
Generic attributes :
9:
Saturation : Unsaturated
24:
Saturation : Saturated
28:
Saturation : Unsaturated
35:
Saturation : Unsaturated

Element Count :
Node 8: Limited

10/566911


N,N2
C,C3

Node 9: Limited
C,C6

Node 28: Limited
N,N3
C,C3

Node 35: Limited
C,C2-4

Uploading L69.str



chain nodes :

7 8 9 10 11 12 22 23 24 26 28

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18

chain bonds :

4-22 7-22 8-9 8-22 9-10 10-11 11-12 11-23 12-14 22-26

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

exact/norm bonds :

4-22 8-9 8-22 9-10 10-11 11-23 12-14 22-26

exact bonds :

7-22 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:Atom 28:CLASS 29:CLASS

Generic attributes :

9:

Saturation : Unsaturated

Element Count :

Node 8: Limited

N,N1

10/566911

Node 26: Limited
N,N3
C,C3

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:24:31 ON 16 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L85

L74	15476	SEA FILE=CAPLUS ABB=ON	PLU=ON	KIM B?/AU
L75	966	SEA FILE=CAPLUS ABB=ON	PLU=ON	MIN Y?/AU
L76	30107	SEA FILE=CAPLUS ABB=ON	PLU=ON	LEE Y?/AU
L77	1881	SEA FILE=CAPLUS ABB=ON	PLU=ON	PARK N?/AU
L78	9952	SEA FILE=CAPLUS ABB=ON	PLU=ON	KIM W?/AU
L79	1	SEA FILE=CAPLUS ABB=ON	PLU=ON	L74 AND L75 AND L76 AND L77 AND L78
L80	13	SEA FILE=CAPLUS ABB=ON	PLU=ON	L74 AND L75 AND L76 AND L77
L81	1	SEA FILE=CAPLUS ABB=ON	PLU=ON	L74 AND L75 AND L76 AND L78
L82	1	SEA FILE=CAPLUS ABB=ON	PLU=ON	L74 AND L75 AND L77 AND L78
L83	1	SEA FILE=CAPLUS ABB=ON	PLU=ON	L74 AND L76 AND L77 AND L78
L84	1	SEA FILE=CAPLUS ABB=ON	PLU=ON	L75 AND L76 AND L77 AND L78
L85	13	SEA FILE=CAPLUS ABB=ON	PLU=ON	(L79 OR L80 OR L81 OR L82 OR L83 OR L84)

=> d ibib abs L85 1-13

L85 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN
ACCESSION NUMBER: 2007:1453308 CAPLUS Full-text
DOCUMENT NUMBER: 148:55079
TITLE: Antifungal azole compounds capable of minimizing liver toxicity caused by long-term dosage and process for preparing the same

10/566911

INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Heo, Jeong Nyung; Lee, Hyuk; Lee, Woo Ghil; Kim, Soung Hwan; Park, No Kyun; Lee, Yan Jeong; Kim, Hyoung Ho

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea

SOURCE: Repub. Korea, No pp. given
CODEN: KRXXFC

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
KR 738228	B1	20070712	KR 2006-17423	20060222
PRIORITY APPLN. INFO.:			KR 2006-17423	20060222

AB Antifungal azole compds. and a process for preparing said compds. are claimed. Said compds. serve to improve antifungal activity, especially against fluconazole-resistant *Candida albicans*, and minimize liver toxicity caused by long-term dosage by enhancing safety of the compds. against the human Cytochrome P 450 enzyme. Antifungal triazole compds. (as represented by a certain formula; no data) or pharmaceutically acceptable salts or isomers thereof are claimed. Substituent groups in this formula may be selected from hydrogen, trifluoromethyl, etc., halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, dioxymethylene group (incomplete list). Antifungal triazole compds. (as represented by a certain formula; no data) are prepared by treating alc. compds. (as represented by a certain formula; no data) with styrene compds. (as represented by a certain formula; no data) in the presence of base in organic solvent. More narrow definitions are indicated; however, specific chemical structures and/or addnl. information are not provided here.

L85 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:714281 CAPLUS Full-text

DOCUMENT NUMBER: 147:150765

TITLE: Arylacrylates for the treatment of bone diseases

INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Lee, Yeon Soo; Heo, Jung Nyung; Lee, Hyuk; Park, No Kyun; Kim, Jung Keun; Kim, Se Won; Ko, Seon Yle

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea; Oscotec Inc.

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
KR 2006134303	A	20061228	KR 2005-53883	20050622
PRIORITY APPLN. INFO.:			KR 2005-53883	20050622

AB A pharmaceutical composition comprising an α -arylmethoxy acrylate derivative is provided to be able to excellently inhibit osteoclast formation and absorption activity thereof, thereby being effectively utilized for preventing metabolic bone diseases such as osteoporosis and ossification at a growth period.

L85 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

10/566911

ACCESSION NUMBER: 2007:99425 CAPLUS Full-text
 DOCUMENT NUMBER: 146:338005
 TITLE: Process for easy preparation of a vinylphosphonate having an α -tributyltin group, used for synthesis of organic phosphorous compounds
 INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Lee, Yeon Soo; Heo, Jung Nyoung; Lee, Hyuk; Lee, Woo Ghil; Kim, Seong Hwan; Park, No Kyun; Heo, Yeon; Minami, Toru
 PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea
 SOURCE: Repub. Korean Kongkai Taeho Kongbo, No pp. given
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2006097214	A	20060914	KR 2005-18285	20050304
PRIORITY APPLN. INFO.:			KR 2005-18285	20050304

AB A method for preparing a vinylphosphonate having an α -tributyltin group is provided to conveniently synthesize a vinylphosphonate by using reactivity of the tributyltin; the latter vinylphosphonate is then used for preparing various compds. To prepare a vinylphosphonate derivative, a vinylphosphonate having an α -tributyltin group prepared by reacting acetylene phosphonate with tributyltin hydride in the presence of Pd catalyst and a solvent is reacted with a halide compound including an R group (R = C2-6 alkyl, aryl, heterocyclic compound such as pyridine, pyrimidine, thiophene, quinoline substituted by alkyl, alkoxy, and halogen) in the presence of Pd catalyst such as Pd(PPh3)4, PdCl2(PPh3)2, BnPdCl(PPh3)2 and Pd2dba3, an inorg. salt and a solvent selected from the group consisting of THF, DMF, N-methylpyrrolidinone, benzene, and toluene.

L85 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:960988 CAPLUS Full-text
 DOCUMENT NUMBER: 145:470053
 TITLE: Process for preparation of alkyl s-(l)-lactate and alkyl r-(d)-o-acyllactate by using lipase which allows to improve preparation yield and optical purity, and enhance separation convenience of product

INVENTOR(S): Lee, Yeon Soo; Kim, Bum Tae; Min, Yong Ki; Heo, Jung Nyoung; Lee, Woo Ghil; Park, No Kyun
 PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea
 SOURCE: Repub. Korean Kongkai Taeho Kongbo, No pp. given
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005103691	A	20051101	KR 2004-28968	20040427
PRIORITY APPLN. INFO.:			KR 2004-28968	20040427
AB	A process for preparation of alkyl S-(L)-lactate and alkyl R-(D)-O-acyllactate by using lipase is provided to improve the preparation yield and optical			

purity, and enhance the separation convenience of the product. The process for preparation of alkyl S-(L)-lactate of formula (2) and alkyl R-(D)-O-acyllactate of formula (3) comprises reacting racemic alkyl lactate of formula (1) in the presence of lipase with carbonyl donor at 0 to 80° for 1 to 100 h to stereoselectively carbonylate a hydroxide group of alkyl R-lactate, wherein R is C1-C10 of saturated or unsatd. alkyl, or alkyl substituted aryl or heteroaryl; R1 is C1-C10 of saturated or unsatd. alkyl, or aryl; and the lipase is derived from *Candida antarctica*.

L85 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:841833 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:241781

TITLE: Compositions comprising methoxyacrylate-based compounds for the treatment of osteoporosis

INVENTOR(S): Kim, Bum Tae; Kim, Ho Soon; Kim, Jung Keun; Kim, Jung Yeo; Kim, Se Won; Ko, Seon Yle; Lee, Byung Eui; Lee, Yeon Soo; Min, Yong Gi; Oh, Kwi Ok; Park, No Gyun
 PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea; Oscotec Inc.

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
 CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005002109	A	20050107	KR 2003-43425	20030630
PRIORITY APPLN. INFO.:			KR 2003-43425	20030630
AB	The composition inhibits osteoclast generation and bone absorption without cytotoxicity to prevent or treat osteoporosis. The pharmaceutical composition for prevention and treatment of osteoporosis is characterized by containing as an active ingredient, a methoxyacrylate-based compd pharmaceutically acceptable carriers.			

L85 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:721491 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:118712

TITLE: Propenoic ester and amide derivatives having fluorostyrene substituent, process for preparing the same and antifungal composition comprising the same
 INVENTOR(S): Kim, Beom Tae; Kim, Jin Cheol; Lee, Yeon Su; Min, Yong Gi; Park, No Gyun

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
 CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2004067218	A	20040730	KR 2003-4230	20030122
PRIORITY APPLN. INFO.:			KR 2003-4230	20030122

AB Propenoic ester and amide derivs. having a fluorostyrene substituent, a process for preparing the same compds. and an antifungal composition comprising the same compds. are provided, which have improved antifungal activity at a low concentration, wide range of antifungal activity, low toxicity and improved duration of efficacy. The process for preparing the propenoic ester and amide derivs. comprises the steps of: reacting a bromide compound with 3-hydroxybenzaldehyde in the presence of base; and Wittig reacting the compound to prepare propenoic ester.

L85 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1350944 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:88045

TITLE: Preparation of α -arylmethoxyacrylates for use in pharmaceutical compositions for preventing and treating metabolic bone diseases

INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Lee, Yeon Soo; Heo, Jung Nyoung; Lee, Hyuk; Park, No Kyun; Kim, Jung-Keun; Kim, Se-Won; Ko, Seon-Yle

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea; Oscotec Inc.

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123054	A1	20051229	WO 2005-KR1935	20050622
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
KR 2005121491	A	20051227	KR 2004-46644	20040622
EP 1784173	A1	20070516	EP 2005-756853	20050622
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1968687	A	20070523	CN 2005-80020330	20050622
JP 2008503567	T	20080207	JP 2007-517956	20050622
PRIORITY APPLN. INFO.:			KR 2004-46644	A 20040622
			WO 2005-KR1935	W 20050622
OTHER SOURCE(S):		CASREACT 144:88045; MARPAT 144:88045		
GI				



AB The title compds. I [A = O, S, CH₂, ON:CH, ON:C(Me); X = H, halo; Y = N, CH; Z = O, NH; R₁ = H, alkyl; R₂ = (un)substituted (hetero)aryl], useful for preventing and treating metabolic bone diseases, were prepared and disclosed. E.g., a multi-step synthesis of (E)-Me 2-(2-([4-(cyclopropylmethyl)phenoxy]methyl)-4-chlorophenyl)-3-methoxyacrylate (II), starting from 2-bromo-5-chlorotoluene, was given. II showed 100% inhibition of osteoclast formation at 1.0 μM.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2005:141060 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:240437

TITLE: Preparation of triazolylmethanol derivatives as antifungal agents

INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Lee, Yeon Soo;

Park, No Kyun; Kim, Woo Jung

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014583	A1	20050217	WO 2004-KR1996	20040809
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
KR 2005017962	A	20050223	KR 2003-55590	20030812
EP 1654254	A1	20060510	EP 2004-748524	20040809
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JP 2007502268	T	20070208	JP 2006-523125	20040809
US 20080027117	A1	20080131	US 2006-566911	20060203
PRIORITY APPLN. INFO.:			KR 2003-55590	A 20030812

OTHER SOURCE(S):
GI

CASREACT 142:240437; MARPAT 142:240437



I



II

AB Title compds. represented by the formula I [wherein A = O, 1,2,4-triazolyl-PhO-, 1,2,4-triazolone-3-yl-PhO-, imidazolone-1-yl-PhO, imidazolinone-1-yl-PhO-; R = H or CF₃; R' = H or alkyl; X = H, halo, (halo)alkyl,alkoxy, 3,4-dioxyalkylene; and pharmaceutically acceptable salts, isomers or esters thereof] were prepared as antifungal agents for the treatment of humans or animals. For example, II was given in a multi-step synthesis starting from the reaction of Me (R)-lactate with morpholine. I showed antifungal activity in vivo against a wide spectrum of pathogenic fungi, such as ATCC 10231 and MYA-573, and low toxicity in oral administration.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:943976 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:155964

TITLE: Method for preparation of fluorine-substituted heterocyclic compounds as intermediate for synthesis of agrochemical and medicinal antagonist

INVENTOR(S): Kim, Beom Tae; Lee, Yeon Su; Min, Yong Gi; Park, No Gyun

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7

DOCUMENT TYPE: Patent
LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

KR 2003031795	A	20030423	KR 2001-63681	20011016
KR 2004043142	A	20040522	KR 2004-21097	20040329
PRIORITY APPLN. INFO.:			KR 2001-63681	A3 20011016

AB Provided are a fluorine-substituted heterocyclic compds., 5-fluoropyrazole derivative and 4-fluoro-6-hydroxypyrimidine, useful as intermediates for the synthesis of agrochems. and medicinal antagonists and methods for preparing them regio selectively in high yields. The fluorine-substituted heterocyclic compds., 5-fluoropyrazole derivative and 4-fluor-6-hydroxy pyrimidine are represented by the formula(1a) or (1b), and formula(2) resp., wherein X is hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy or C1-C4 arylalkoxy; RF is fluorine or trifluoromethyl; and R1, R2 and R3 are individually hydrogen, C1-4 alkyl, C1-4 aryl or C1-4 arylalkyl. They are manufactured by one pot reaction with a substituted hydrazine derivative and a guanidine derivative using Me 2-fluoralkyl 2-phenylacetate derivative as a starting material.

L85 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:923755 CAPLUS Full-text
 DOCUMENT NUMBER: 142:113616
 TITLE: Preparation of novel propanoic ester and amide derivatives having oxime group as branched chain and disinfectant composition containing the same
 INVENTOR(S): Kim, Beom Tae; Kim, Gyeong Man; Kim, Heung Tae; Lee, Yeon Su; Min, Yong Gi; Park, No Gyun
 PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea
 SOURCE: Repub. Korean Kongkai Taeho Kongbo, No pp. given
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
KR 2002040158	A	20020530	KR 2000-70103	20001123
PRIORITY APPLN. INFO.:			KR 2000-70103	20001123
AB	<p>Provided are novel propanoic ester and amide derivs. having an oxime group as a branched chain, which are excellent in disinfecting activity, a preparation thereof, and a disinfectant composition containing the propanoic ester and amide derivs. The propanoic ester and amide derivs. represented by the formula 1 are produced by a process comprising the steps of: reacting a bromine compound represented by the formula 2 and 2,3-butanedione monoxime represented by the formula 3 in the presence of a base to produce an oxime-based ketone compound; reducing the oxime-based ketone compound or condensing the oxime-based ketone compound with a hydroxy amine to produce an oxime-based alc. compound or a dioxime-based compound; reacting the oxime-based alc. compound or the dioxime-based compound with a Pr fluoride compound in the presence of a base. In the formula, R1 is trifluoromethyl, R2 is a Ph group, X is CH or N, and Y is O or NH.</p>			

L85 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN



ACCESSION NUMBER: 2004:370917 CAPLUS Full-text
 DOCUMENT NUMBER: 140:391189
 TITLE: Preparation of furan derivatives for treatment of osteoporosis
 INVENTOR(S): Kim, Jung-Keun; Kim, Se-Won; Oh, Kwi-Ok; Ko, Seon Yle; Kim, Jong Yeo; Lee, Byung-Eui; Kim, Bum Tae; Lee, Yeon Soo; Min, Yong Ki; Park, No Gyun

10/566911

PATENT ASSIGNEE(S): Oscotec Inc., S. Korea; Korea Research Institute of Chemical Technology
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037804	A1	20040506	WO 2003-KR2231	20031022
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
KR 2004035559	A	20040429	KR 2003-72536	20031017
AU 2003273096	A1	20040513	AU 2003-273096	20031022
JP 2006515276	T	20060525	JP 2004-546535	20031022
US 20060004088	A1	20060105	US 2005-531714	20050418
KR 2005080452	A	20050812	KR 2005-56454	20050628
PRIORITY APPLN. INFO.:			KR 2002-64670	A 20021022
			KR 2003-72536	A 20031017
			WO 2003-KR2231	W 20031022

OTHER SOURCE(S): MARPAT 140:391189
 GI



AB The title compds. I [wherein X = H, (un)substituted OH, or NH₂; Y = SC(=NH)NH₂, (un)substituted OH, or NH₂] or pharmaceutically acceptable salts thereof are prepd for the treatment of bone disease. For example, the compound II was obtained by extraction from a plant rehmannia glutinosa libosch. I showed strong effect on bone proliferation with the side effect reduced. I also showed high inhibition rate against osteoclast formation at different concns. Formulations containing I as an active ingredient were also described.

L85 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:319855 CAPLUS Full-text
 DOCUMENT NUMBER: 138:321015
 TITLE: Process for the monoesterification of dihydroxybenzene using carboxylic anhydrides or halides
 INVENTOR(S): Lee, Yeon-Soo; Kim, Bum-Tae; Min, Yong-Ki; Park, No-Kyun; Kim, Ki-Ho; Kim, Ki-Soo; Park, No-Kyun
 PATENT ASSIGNEE(S): Bioland Co., Ltd., S. Korea; Korea Research Institute

SOURCE: of Chemical Technology
PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033449	A1	20030424	WO 2002-KR1915	20021014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2003032301	A	20030426	KR 2001-64008	20011017
AU 2002353549	A1	20030428	AU 2002-353549	20021014
US 20040260114	A1	20041223	US 2004-490673	20040324
US 6933403	B2	20050823		

PRIORITY APPLN. INFO.: KR 2001-64008 A 20011017
WO 2002-KR1915 W 20021014

OTHER SOURCE(S): CASREACT 138:321015; MARPAT 138:321015
AB Dihydroxybenzenes (e.g., hydroquinone) are monoesterified [i.e., the production of 4-(acetyloxy)phenol] by their reaction with carboxylic anhydrides (e.g., acetic anhydride) or halides in the absence of organic or inorg. bases.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L85 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:924331 CAPLUS Full-text

DOCUMENT NUMBER: 136:37895

TITLE: Preparation of arbutin intermediates by stereoselective glycosylation reaction of hydroquinones

INVENTOR(S): Lee, Yeon Soo; Kim, Bum Tae; Min, Yong Ki; Park, No Kyum; Kim, Ki Ho; Lee, Jae Seob; Jeoung, See Wha; Kim, Ki Soo

PATENT ASSIGNEE(S): Bioland Co., Ltd., S. Korea; Korea Research Institute of Chemical Technology

SOURCE: U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010053846	A1	20011220	US 2001-838841	20010420
US 6388103	B2	20020514		

PRIORITY APPLN. INFO.: KR 2000-27129 A 20000519

OTHER SOURCE(S): CASREACT 136:37895; MARPAT 136:37895

GI



I

AB The invention is related to a preparation method of arbutin intermediates I wherein R is hydrogen, alkyl or cycloalkyl group with 1 to 10 carbon, or aliphatic or aromatic acyl group with 1 to 10 carbon by stereoselective glycosylation reaction of hydroquinones with penta-acetyl- β -D-glucose in the presence of Lewis-acid and base catalysts. Thus, stereoselective glycosylation of mono-benzoyl hydroquinone with penta-acetyl- β -D-glucose in the presence of NEt₃ and borontrifluoride diethyl-etherate as Lewis-acid catalyst in CH₂Cl₂ gave benzoyl tetra-acetyl-arbutin in 90 % yield.

=> file medline embase biosis wpix

FILE 'MEDLINE' ENTERED AT 14:25:22 ON 16 APR 2008

FILE 'EMBASE' ENTERED AT 14:25:22 ON 16 APR 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:25:22 ON 16 APR 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'WPIX' ENTERED AT 14:25:22 ON 16 APR 2008

COPYRIGHT (C) 2008 THE THOMSON CORPORATION

=> s L85

L87 14 L85

=> dup rem L85 L87

FILE 'CAPLUS' ENTERED AT 14:25:36 ON 16 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 14:25:36 ON 16 APR 2008

COPYRIGHT (C) 2008 THE THOMSON CORPORATION

PROCESSING COMPLETED FOR L85

PROCESSING COMPLETED FOR L87

L88 15 DUP REM L85 L87 (12 DUPLICATES REMOVED)

ANSWERS '1-13' FROM FILE CAPLUS

ANSWERS '14-15' FROM FILE WPIX

=> d iall L88 14-15

10/566911

L88 ANSWER 14 OF 15 WPIX COPYRIGHT 2008 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2007-338836 [32] WPIX Full-text
 DOC. NO. CPI: C2007-123728 [32]
 TITLE: Method for preparing alkyl lactate with high yield and high purity from lactide through alcoholysis using lipase D16; E17
 DERWENT CLASS:
 INVENTOR: HEO J N; KIM B T; LEE W G; LEE Y S; MIN Y K; PARK N K
 PATENT ASSIGNEE: (KORE-N) KOREA PES INST CHEM TECHNOLOGY
 COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
KR 592794	B1	20060628	(200732)*	KO	[1]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
KR 592794	B1	KR 2005-8936	20050201

PRIORITY APPLN. INFO: KR 2005-1043 20050106
 INT. PATENT CLASSIF.:
 IPC ORIGINAL: C12P0041-00 [I,A]; C12P0041-00 [I,C]; C12P0007-40 [I,C]; C12P0007-56 [I,A]

BASIC ABSTRACT:

KR 592794 B1 UPAB: 20070521

NOVELTY - A method for preparing alkyl lactate is provided to obtain alkyl SS-(L)-O-lactyl lactate and/or alkyl R-(D)-lactate with high yield and high optical purity from racemic lactide or R- or S-isomer thereof.

DETAILED DESCRIPTION - Preparation of alkyl SS-(L)-O-lactyl lactate of formula (2b) and alkyl R-(D)-lactate of formula (3a) comprises alcoholizing a racemic lactide of formula(1) at a temperature of 0-80degreesC for 1-500 hours in the presence of a lipase enzyme catalyst derived from Candida antarctica.

R=1-10C saturated or unsaturated alkyl. MANUAL CODE: CPI:

D05-A02C; D05-C; E10-E04D2; E11-G03; E11-M

L88 ANSWER 15 OF 15 WPIX COPYRIGHT 2008 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2004-632320 [61] WPIX Full-text
 CROSS REFERENCE: 2003-826059
 DOC. NO. CPI: C2004-227157 [61]
 TITLE: Fluorine-substituted heterocyclic compounds as intermediate for synthesis of agrochemicals and medicaments and method for preparing the same
 DERWENT CLASS: B03; C02; E13
 INVENTOR: KIM B T; LEE Y S; MIN Y G; PARK N G
 PATENT ASSIGNEE: (KORE-N) KOREA RES INST CHEM TECHNOLOGY
 COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
KR 2004043142	A	20040522	(200461)*	KO	1[10]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

10/566911

KR 2004043142 A

KR 2004-21097 20040329

PRIORITY APPLN. INFO: KR 2004-21097

20040329

INT. PATENT CLASSIF.:

MAIN: C07D239-36

BASIC ABSTRACT:

KR 2004043142 A UPAB: 20060122

NOVELTY - A fluorine-substituted heterocyclic compound as an intermediate for synthesis of agrochemicals and medicaments and a method for preparing the same are provided, thereby regio-selectively preparing the 5-fluoro-pyrazole derivative and 4-fluoro-6-hydroxy pyrimidine derivative in higher yield.

DETAILED DESCRIPTION - A method for preparing a 4-fluoro-6-hydroxy pyrimidine derivative with substituted phenyl at C3 or C4 position represented by the formula(2) comprises reacting a methyl 2-fluoroalkyl 2-phenylacetate derivative of the formula(3) with a substituted guanidine derivative(R₂C(NH₂)=NH) in the presence of an solvent, wherein X is hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy or C1-4 arylalkoxy; RF is fluorine or trifluoromethyl; R₃ is hydrogen, C1-4 alkyl, C1-4 aryl or C1-4 arylalkyl; the solvent is acetonitrile, 1,4-dioxane, or 5 to 30 % 1,4-dioxane solution; and the reaction temperature is 60 to 120 deg. C. MANUAL

CODE:

CPI: B07-D08; B07-D12; B10-H02A; B11-C01; C07-D08;

C07-D12; C10-H02A; C11-C01; C14-T; E07-D08; E07-D12

=> file registry
 FILE 'REGISTRY' ENTERED AT 14:25:56 ON 16 APR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8
 DICTIONARY FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

Uploading L15.str



```
chain nodes :
7 8 9 10 11 12 22 23 24
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
4-22 7-22 8-9 8-22 9-10 10-11 11-12 11-23 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
4-22 7-22 8-9 8-22 9-10 10-11 11-23 12-14
exact bonds :
11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
```


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:CLASS

10/566911

11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 22:CLASS
 23:CLASS 24:CLASS
 25:CLASS
 Generic attributes :
 9:
 Saturation : Unsaturated
 Element Count :
 Node 8: Limited
 N,N1

Uploading L45.str



chain nodes :
 7 8 9 10 11 12 21 22 24 27 30 31 36 38
 ring nodes :
 1 2 3 4 5 6 13 14 15 16 17 18
 chain bonds :
 4-27 7-27 8-9 8-27 9-10 10-11 11-12 11-21 12-14 12-38 27-36
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
 exact/norm bonds :
 4-27 8-9 8-27 9-10 11-21 12-38 27-36
 exact bonds :
 7-27 10-11 11-12 12-14
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

G1:[*1],[*2]

G2:H,CF3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 21:CLASS
 22:CLASS 24:CLASS
 25:CLASS 26:CLASS 27:Atom 30:CLASS 31:Atom 36:CLASS 38:CLASS
 Generic attributes :
 9:
 Saturation : Unsaturated
 27:
 Saturation : Saturated
 31:

10/566911

Saturation : Unsaturated

Element Count :

Node 8: Limited

N,N2

C,C3

Node 9: Limited


C,C6

Node 31: Limited

N,N3

C,C3

Uploading L59.str



chain nodes :

7 8 9 10 19 20 21 24 27 28 33 35

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16

chain bonds :

4-24 7-24 8-9 8-24 9-10 10-35 12-35 19-35 24-33

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

exact/norm bonds :

4-24 8-9 8-24 9-10 10-35 12-35 19-35 24-33

exact bonds :

7-24

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

G1:[*1],[*2]

G2:H,CF3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:Atom 20:Atom 21:Atom

22:CLASS 23:CLASS

24:Atom 27:CLASS 28:Atom 33:CLASS 35:CLASS

Generic attributes :

9:

Saturation : Unsaturated

10/566911

24:
Saturation : Saturated
28:
Saturation : Unsaturated
35:
Saturation : Unsaturated


Element Count :
Node 8: Limited
N,N2
C,C3

Node 9: Limited
C,C6

Node 28: Limited
N,N3
C,C3

Node 35: Limited
C,C2-4

Uploading L69.str



chain nodes :
7 8 9 10 11 12 22 23 24 26 28
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18
chain bonds :
4-22 7-22 8-9 8-22 9-10 10-11 11-12 11-23 12-14 22-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
4-22 8-9 8-22 9-10 10-11 11-23 12-14 22-26
exact bonds :
7-22 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 22:CLASS
23:CLASS 24:CLASS

10/566911

25:CLASS 26:Atom 28:CLASS 29:CLASS

Generic attributes :

9:

Saturation : Unsaturated

Element Count :

Node 8: Limited

N,N1

Node 26: Limited

N,N3

C,C3

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:25:59 ON 16 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16

FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L18

L15 STR



Structure attributes must be viewed using STN Express query preparation.

L17 127 SEA FILE=REGISTRY SSS FUL L15
L18 1 SEA FILE=CAPLUS ABB=ON PLU=ON L17

=> file beilstein

FILE 'BEILSTEIN' ENTERED AT 14:26:07 ON 16 APR 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

*** FILE CONTAINS 10.322,808 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
separate documents and can not be searched together in one query.
Reaction data for BEILSTEIN compounds may be displayed
immediately with the display codes PRE (preparations) and REA
(reactions). A substance answer set retrieved after the search
for a chemical name, a compounds with available reaction
information by combining with PRE/FA, REA/FA or more generally
with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
between a BEILSTEIN compound and belonging reactions. For mo
detailed reaction searches BRNs can be searched as reaction
partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<


```
*****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.          *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE    *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                  *
* FOR PRICE INFORMATION SEE HELP COST                          *
*****
```

>>> Price change as of January 1st, 2008: Connect Time and Structure
Search fees re-introduced. See NEWS and HELP COST <<<

=> d stat que L20

L15 STR

10/566911



Structure attributes must be viewed using STN Express query preparation.
L20 0 SEA FILE=BEILSTEIN SSS FUL L15

100.0% PROCESSED 109 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

=> file marpat
FILE 'MARPAT' ENTERED AT 14:26:24 ON 16 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 148 ISS 14 (20080411/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):


US	20080051413	28	FEB	2008
DE	102006039038	21	FEB	2008
EP	1889831	20	FEB	2008
JP	2008044933	28	FEB	2008
WO	2008028336	13	MAR	2008
GB	2440819	13	FEB	2008
FR	2904973	22	FEB	2008
RU	2317993	27	FEB	2008
CA	2593150	06	JAN	2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT have increased from 100,000 to 200,000 for both on-line and batch searches. For more information on MARPAT search limits, type HELP SLIMITS at an arrow prompt.

=> d stat que L62
L15 STR

10/566911




Structure attributes must be viewed using STN Express query preparation.

L22 215 SEA FILE=MARPAT SSS FUL L15

L45 STR

H 1

Hy 2




G1 [01], [02]

G2 H, CF3

Structure attributes must be viewed using STN Express query preparation.

L47 99 SEA FILE=MARPAT SUB=L22 SSS FUL L45

L59 STR



Structure attributes must be viewed using STN Express query preparation.

L71 17 SEA FILE=MARPAT SUB=L22 SSS FUL L69
L72 17 SEA FILE=MARPAT ABB=ON PLU=ON L71/COM

=> s L62 or L72

L89 36 L62 OR L72

=> d ibib abs hitstr L18 tot; d ibib abs qhit L89 1-36

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:141060 CAPLUS Full-text

DOCUMENT NUMBER: 142:240437

TITLE: Preparation of triazolymethanol derivatives as antifungal agents

INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Lee, Yeon Soo; Park, No Kyun; Kim, Woo Jung

PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S. Korea

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014583	A1	20050217	WO 2004-KR1996	20040809
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,			

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG


KR 2005017962	A	20050223	KR 2003-55590	20030812
EP 1654254	A1	20060510	EP 2004-748524	20040809

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK


JP 2007502268	T	20070208	JP 2006-523125	20040809
US 20080027117	A1	20080131	US 2006-566911	20060203

PRIORITY APPLN. INFO.: KR 2003-55590 A 20030812
 WO 2004-KR1996 W 20040809

OTHER SOURCE(S): CASREACT 142:240437; MARPAT 142:240437
 GI



I



II

AB Title compds. represented by the formula I [wherein A = O, 1,2,4-triazolyl-PhO-, 1,2,4-triazolone-3-yl-PhO-, imidazolone-1-yl-PhO-, imidazolinone-1-yl-PhO-; R = H or CF₃; R' = H or alkyl; X = H, halo, (halo)alkyl,alkoxy, 3,4-dioxyalkylene; and pharmaceutically acceptable salts, isomers or esters thereof] were prepared as antifungal agents for the treatment of humans or animals. For example, II was given in a multi-step synthesis starting from the reaction of Me (R)-lactate with morpholine. I showed antifungal activity in vivo against a wide spectrum of pathogenic fungi, such as ATCC 10231 and MYA-573, and low toxicity in oral administration.

IT 644878-16-6P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of difluorophenyl triazolylmethanol derivs. as antifungal agents)


RN 844878-16-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.

10/566911

Double bond geometry unknown.



IT 644877-73-2P 844877-76-5P 844877-80-1P
 844877-81-2P 844877-82-3P 844877-83-4P
 844877-84-5P 844877-85-6P 844877-86-7P
 844877-87-8P 844877-88-9P 844877-89-0P
 844877-90-3P 844877-91-4P 844877-92-5P
 844877-93-6P 844877-94-7P 844877-95-8P
 844877-96-9P 844877-97-0P 844877-98-1P
 844877-99-2P 844878-00-8P 844878-01-9P
 844878-02-6P 844878-03-1P 844878-04-2P
 844878-05-3P 844878-06-4P 844878-07-5P
 844878-08-6P 844878-09-7P 844878-10-0P
 844878-11-1P 844878-12-2P 844878-13-3P
 844878-14-4P 844878-15-5P 844878-17-7P
 844878-18-8P 844878-19-9P 844878-20-2P
 844878-21-3P 844878-22-4P 844878-23-5P
 844878-24-6P 844878-25-7P 844878-26-8P
 844878-27-9P 844878-28-0P 844878-29-1P
 844878-30-4P 844878-31-5P 844878-32-6P
 844878-33-7P 844878-34-8P 844878-35-9P
 844878-36-0P 844878-37-1P 844878-38-2P
 844878-39-3P 844878-40-6P 844878-41-7P
 844878-42-8P 844878-43-9P 844878-44-0P
 844878-45-1P 844878-47-3P 844878-48-4P
 844878-49-5P 844878-50-8P 844878-51-9P
 844878-52-0P 844878-53-1P 844878-54-2P
 844878-55-3P 844878-56-4P 844878-57-5P
 844878-58-6P 844878-60-0P 844878-61-1P
 844878-62-2P 844878-63-3P 844878-64-4P
 844878-65-5P 844878-67-7P 844878-69-9P
 844878-71-3P 844878-73-5P 844878-75-7P
 844878-77-9P 844878-79-1P 844878-81-5P
 844878-83-7P 844878-85-9P 844878-87-1P
 844878-89-3P 844878-90-6P 844878-92-8P
 844878-94-0P 844878-96-2P 844878-98-4P
 844879-02-3P 844879-05-6P 844879-08-9P
 844879-11-4P 844879-13-6P 844879-15-8P
 844879-17-0P 844879-19-2P 844879-21-6P
 844879-23-8P 844879-25-0P 844879-26-1P
 844879-28-3P 844879-30-7P 844879-32-9P
 844879-34-1P 844879-36-3P 844879-38-5P
 844879-41-0P 844879-44-3P 844879-46-5P
 844879-48-7P 844879-50-1P 844879-53-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10/566911

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of difluorophenyl triazolylmethanol derivs. as antifungal
agents)

RN 844877-73-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -[(1R)-1-[(1E)-2-(4-chlorophenyl)-
1,3,3,3-tetrafluoro-1-propenyl]oxy]ethyl)- α -(2,4-difluorophenyl)-,
(α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 844877-76-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -[(1R)-1-[(1Z)-2-(4-chlorophenyl)-
1,3,3,3-tetrafluoro-1-propenyl]oxy]ethyl)- α -(2,4-difluorophenyl)-,
(α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 844877-80-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-
[(1E)-1,3,3,3-tetrafluoro-2-[4-(trifluoromethyl)phenyl]-1-
propenyl]oxy]ethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 844877-81-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[2-(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]ethyl]-, (1Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 844877-82-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[2-(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]ethyl]-, (1Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-83-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[2-(1,3,3,3-tetrafluoro-1-propenyl)oxy]ethyl]-, (1Z)- (9CI) (CA INDEX NAME)

10/566911


Absolute stereochemistry.
Double bond geometry unknown.



RN 844877-84-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-α-[(1R)-1-[[2-(4-ethoxyphenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]ethyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 844877-85-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-α-[(1R)-1-[[2-(4-(1,1-dimethylethyl)phenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




10/566911

RN 844877-86-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -[(1R)-1-[[2-(4-bromophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]ethyl]- α -(2,4-difluorophenyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-87-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[[(1E)-1,3,3,3-tetrafluoro-2-(4-methylphenyl)-1-propenyl]oxy]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 844877-88-9 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[[(1Z)-1,3,3,3-tetrafluoro-2-(4-methylphenyl)-1-propenyl]oxy]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

10/566911




RN 844877-89-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[1,3,3,3-tetrafluoro-2-(3-methoxyphenyl)-1-propenyl]oxy]ethyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-90-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[1,3,3,3-tetrafluoro-2-[3-(trifluoromethyl)phenyl]-1-propenyl]oxy]ethyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-91-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[1E)-1-fluoro-2-(4-phenoxyphenyl)ethenyl]oxy]ethyl]-, (α R)- (CA INDEX NAME)

10/566911

INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 844877-92-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-
[[1-fluoro-2-(4-methoxyphenyl)ethenyl]oxy]ethyl]-, (α R)- (CA INDEX
NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 844877-93-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-
[[2-(3,5-dimethylphenyl)-1-fluoroethenyl]oxy]ethyl]-, (α R)- (CA
INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




10/566911

RN 844877-94-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-
[[2-(4-ethylphenyl)-1-fluoroethenyl]oxy]ethyl]-, (α R)- (CA INDEX
NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-95-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -[(1R)-1-[[2-(4-butylphenyl)-1-
fluoroethenyl]oxy]ethyl]- α -(2,4-difluorophenyl)-, (α R)- (CA
INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-96-9 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-
[[1-fluoro-2-(4-methylphenyl)ethenyl]oxy]ethyl]-, (α R)- (CA INDEX
NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-97-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[1-fluoro-2-(4-fluorophenyl)ethenyl]oxy]ethyl]-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-98-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -[(1R)-1-[[2-(1,3-benzodioxol-5-yl)-1-fluoroethenyl]oxy]ethyl]- α -(2,4-difluorophenyl)-, (α R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844877-99-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-[[{(1Z)-1-fluoro-2-(4-phenoxyphenyl)ethenyl]oxy]ethyl]-, (α R)- (CA INDEX NAME)

10/566911


Absolute stereochemistry.
Double bond geometry as shown.



RN 844878-00-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- α -[(1R)-1-
[[2-[4-(1,1-dimethylethyl)phenyl]-1-fluoroethenyl]oxy]ethyl]-, (α R)-
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 844878-01-9 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-
[4-[[1,3,3,3-tetrafluoro-2-(4-methylphenyl)-1-propenyl]oxy]phenyl]- α -
(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 844878-02-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-03-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(4-fluorophenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-04-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(1,3-benzodioxol-5-yl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/566911




RN 844878-05-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(3-(trifluoromethyl)phenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-06-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(3-fluorophenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-07-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(3,5-dichlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-08-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(4-methoxyphenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-09-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(3-methoxyphenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 844878-10-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-(3,4-dimethylphenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 844878-11-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-(3,5-dimethylphenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 844878-12-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-[(1,1-dimethylethyl)phenyl]-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-13-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(4-phenoxyphenyl)ethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-14-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(3-methylphenyl)ethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 844878-15-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-(4-ethoxyphenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.




RN 844878-17-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(4-fluorophenyl)ethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.






RN 844878-21-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-[3-(1-methylethoxy)phenyl]ethenyl]oxy]phenyl]-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-22-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(3-methoxyphenyl)ethenyl]oxy]phenyl]-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844878-23-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-(4-ethylphenyl)-1-fluoroethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-24-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-(3,5-dimethylphenyl)-1-fluoroethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-25-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(3-methylphenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-26-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-butylphenyl)-1,3,3,3-tetrafluoro-1-propenyloxy]phenyl]- α -(2,4-difluorophenyl)- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-27-9 CAPLUS


CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(4-phenoxyphenyl)-1-propenyloxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)-, (α R, β R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.




RN 844878-28-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(3-methylphenyl)ethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)

RN 844878-29-1 CAPLUS


CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(3-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)

RN 844878-30-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[(1-fluoro-2-phenylethenyl)oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)


RN 844878-31-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-32-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(4-fluorophenyl)ethenyl]oxy]phenyl]- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-33-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(1,3-benzodioxol-5-yl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- β -methyl- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-34-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)- β -methyl-3-[4-[[1,3,3,3-tetrafluoro-2-(3-methoxyphenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-35-9 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(3,5-dichlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-36-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(4-methylphenyl)ethenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-37-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(4-methoxyphenyl)ethenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-38-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[(1-fluoro-2-phenylethenyl)oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-39-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-40-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(3-methylphenyl)ethenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-41-7 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-42-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[1,3,3,3-tetrafluoro-2-(4-methylphenyl)-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-43-9 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-44-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1,3,3,3-tetrafluoro-2-[3-(trifluoromethyl)phenyl]-1-propenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-45-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(1,3-benzodioxol-5-yl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-47-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1,3,3,3-tetrafluoro-2-(3-methylphenyl)-1-propenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-48-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(3-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-49-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1,3,3,3-tetrafluoro-2-(3-fluorophenyl)-1-propenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-50-8 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1,3,3,3-tetrafluoro-2-(3-methoxyphenyl)-1-propenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 844878-51-9 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[2-(3,5-dimethylphenyl)-1-fluoroethenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-52-0 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-[3-(1-methylethoxy)phenyl]ethenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-53-1 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α-(2,4-difluorophenyl)-3-[4-[[1-fluoro-2-(4-fluorophenyl)ethenyl]oxy]phenyl]-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-54-2 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(3-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-55-3 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-chloro-3-methylphenyl)-1-fluoroethenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-56-4 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(1,3-benzodioxol-5-yl)-1-fluoroethenyl]oxy]phenyl]-α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-57-5 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, α -(2,4-difluorophenyl)-3-[4-[[2-(3,5-dimethylphenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]- α -(1H-1,2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 844878-58-6 CAPLUS

CN 1H-1,2,4-Triazole-1-ethanol, 3-[4-[[2-(4-butylphenyl)-1-fluoroethenyl]oxy]phenyl]- α -(2,4-difluorophenyl)- α -(1H-1,2,4-triazol-1-ylmethyl)- (CA INDEX NAME)




RN 844878-60-0 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-[4-[[1-fluoro-2-(3-methylphenyl)ethenyl]oxy]phenyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-61-1 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(4-methoxyphenyl)ethenyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-62-2 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(4-methoxyphenyl)ethenyl]oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844878-63-3 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro-3-[4-[[1,3,3,3-tetrafluoro-2-(4-methylphenyl)-1-propenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-64-4 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1,3,3,3-tetrafluoro-2-(4-methylphenyl)-1-propenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RN 844878-65-5 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-[4-[[1-fluoro-2-(4-methoxyphenyl)ethenyl]oxy]phenyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.

RN 844878-71-3 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(3,5-dichlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-73-5 CAPLUS

CN 2H-Imidazol-2-one, 1-[4-[[2-(3-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-75-7 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(1,3-benzodioxol-5-yl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/566911




RN 844878-77-9 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-[4-[(1-fluoro-2-phenylethenyl)oxy]phenyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-79-1 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-[4-[[2-(4-ethylphenyl)-1-fluoroethenyl]oxy]phenyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844878-81-5 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[4-[[2-(4-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-83-7 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[4-[[2-(3-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-85-9 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[(1-fluoro-2-phenylethenyl)oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-87-1 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[4-[[2-(1,3-benzodioxol-5-yl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-89-3 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844878-90-6 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[4-[[2-(3,4-dichlorophenyl)-1-fluoroethenyl]oxy]phenyl]-2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-92-8 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(3-methylphenyl)ethenyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-94-0 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro-3-[4-[[1,3,3,3-tetrafluoro-2-(4-methoxyphenyl)-1-propenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-96-2 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-3-[4-[(1-fluoro-2-phenylethenyl)oxy]phenyl]-(CA INDEX NAME)]

Absolute stereochemistry.

Double bond geometry unknown.




RN 844878-98-4 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-3-[4-[[2-(4-ethylphenyl)-1-fluoroethenyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)]

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844879-02-3 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[2-(4-ethylphenyl)-1-fluoroethenyl]oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-05-6 CAPLUS

CN 2H-Imidazol-2-one, 1-[4-[[2-(4-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-08-9 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(4-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-11-4 CAPLUS

CN 2H-Imidazol-2-one, 1-[4-[[2-(3-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-13-6 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(3-chlorophenyl)-1-fluoroethenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844879-15-8 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(3-fluorophenyl)ethenyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-17-0 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(3-fluorophenyl)ethenyl]oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-19-2 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro-4-[4-[(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/566911




RN 844879-21-6 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro-4-[4-[[1,3,3,3-tetrafluoro-2-(3-methylphenyl)-1-propenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-23-8 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 4-[4-[[2-(3-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-2,4-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844879-25-0 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro-3-[4-[(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-26-1 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[(1,3,3,3-tetrafluoro-2-phenyl-1-propenyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-28-3 CAPLUS

CN 2H-Imidazol-2-one, 1-[4-[[2-(1,3-benzodioxol-5-yl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/566911




RN 844879-30-7 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(3-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-32-9 CAPLUS

CN 2H-Imidazol-2-one, 1-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844879-34-1 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro-3-[[4-[[1,3,3,3-tetrafluoro-2-(3-methoxyphenyl)-1-propenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-36-3 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[[4-[[1-fluoro-2-(3-methoxyphenyl)ethenyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-38-5 CAPLUS

CN 2H-Imidazol-2-one, 1-[4-[[2-(1,3-benzodioxol-5-yl)-1-fluoroethenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

10/566911




RN 844879-41-0 CAPLUS

CN 2H-Imidazol-2-one, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(4-methylphenyl)ethenyl]oxy]phenyl]-1,3-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-44-3 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(4-chlorophenyl)-1,3,3,3-tetrafluoro-1-propenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




10/566911

RN 844879-46-5 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1,3,3,3-tetrafluoro-2-(3-methoxyphenyl)-1-propenyl]oxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-48-7 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(3-methoxyphenyl)ethenyl]oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-50-1 CAPLUS

CN 2-Imidazolidinone, 1-[4-[[2-(1,3-benzodioxol-5-yl)-1-fluoroethenyl]oxy]phenyl]-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 844879-53-4 CAPLUS

CN 2-Imidazolidinone, 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-[[1-fluoro-2-(4-methylphenyl)ethenyl]oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 1 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 148:262617 MARPAT [Full-text](#)

TITLE: Preparation of pyrimidine- and triazine-derivative endothelin receptor antagonists

INVENTOR(S): Riechers, Hartmut; Klinge, Dagmar; Amberg, Wilhelm; Kling, Andreas; Mueller, Stefan; Baumann, Ernst; Rheinheimer, Joachim; Vogelbacher, Uwe Josef; Wernet, Wolfgang; Unger, Lilliane; Raschack, Manfred

PATENT ASSIGNEE(S): Abbott Gmbh & Co. KG, Germany

SOURCE: U.S., 18pp., Cont. of U.S. Ser. No. 748,184.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE


US 7109205	B2	20060919	US 2003-602275	20030624
US 20040092742	A1	20040513		
DE 19533023	A1	19960418	DE 1995-19533023	19950907
DE 19533023	B4	20070516		
WO 9611914	A1	19960425	WO 1995-EP3963	19951007
W: AU, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1110952	A1	20010627	EP 2001-103889	19951007
EP 1110952	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
US 5932730	A	19990803	US 1997-809699	19970327
US 5969134	A	19991019	US 1998-184152	19981102
US 6197958	B1	20010306	US 1999-309770	19990511
US 20020052495	A1	20020502	US 2000-748184	20001227
US 6600043	B2	20030729		
US 20060160808	A1	20060720	US 2006-377879	20060316
US 7119097	B2	20061010		
US 20060276645	A1	20061207	US 2006-502257	20060810
US 20060276474	A1	20061207	US 2006-502293	20060810
US 20070203338	A1	20070830	US 2007-789630	20070425
PRIORITY APPLN. INFO.:				
			DE 1994-4436851	19941014
			DE 1995-19533023	19950907
			WO 1995-EP3963	19951007
			US 1997-809699	19970327
			US 1998-184152	19981102
			US 1999-309770	19990511
			US 2000-748184	20001227
			EP 1995-935916	19951007
			US 2003-602275	20030624
			US 2006-502257	20060810

GI



AB The title compds. I [R = CHO, tetrazolyl, CN, CO₂H, groups cleavable to CO₂H; R² = (un)substituted NH₂, halogen, (un)substituted alkyl, etc.; R³ = H, OH, (un)substituted NH₂, halogen, (un)substituted alkyl, etc.; R⁴, R⁵ = (un)substituted Ph or naphthyl; R⁶ = H, alkyl, alkenyl, alkynyl, alkylcarbonyl, (un)substituted Ph, etc.; X = N, (un)substituted CH; Y = direct bond, S, O; Z = S, O, SO, SO₂, direct bond], and their pharmaceutically acceptable salts, are prepared and disclosed as endothelin receptor antagonists. In receptor binding assays, pyrimidine derivative II (R² and R³ = MeO), m.p. 167°, demonstrated a K_i ETA of 6 nM. In particular, the racemate and individual enantiomers of II (R² and R³ = Me) are claimed.

MSTR 1A



G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G26 = carbon chain <containing 1-8 C,
 0 or more double bonds, 0 or more triple bonds>
 (opt. substd. by G27)
 G27 = halo / Ph (opt. substd. by 1 or more G28)
 G33 = O
 G34 = O
 Patent location: disclosure
 Note: substitution is restricted


REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 2 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 147:9932 MARPAT Full-text
 TITLE: Preparation of pyrimidinyl-oxy-propionates and related compounds as endothelin antagonists
 INVENTOR(S): Amberg, Wilhelm; Baumann, Ernst; Hergenroeder, Stefan; Kling, Andreas; Klinge, Dagmar; Raschack, Manfred; Riechers, Hartmut; Schult, Sabine; Unger, Liliane
 PATENT ASSIGNEE(S): Germany
 SOURCE: Hung. Pat. Appl., 51pp.
 CODEN: HUXXCV
 DOCUMENT TYPE: Patent
 LANGUAGE: Hungarian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 9903371	A2	20000228	HU 1999-3371	19970404
HU 9903371	A3	20000428		
PRIORITY APPLN. INFO.:			HU 1999-3371	19970404


GI



AB Pyrimidinyl-oxy-propionates I, wherein R is a group that can be hydrolyzed into a tetrazolyl, nitrile, carboxy; R2 is H, halogen, OH, NH2, NH(alkyl),

N(alkyl)2, alkyl, halogen-alkyl, alkoxy, halogen-alkoxy, alkyl-thio; or it forms a 5 or 6-member ring with CR2; X = N, substituted C; Y is N or CH; Z is O, S; R3 is H, halogen, OH, NH2, NH(alkyl), N(alkyl)2, alkyl, halogen-alkyl, alkoxy, halogen-alkoxy, alkoxy-amino, alkyl-thio; or it forms a 5 or 6 member ring with CR3; R4, R5 in a certain case, is Ph or a substituted Ph or naphthyl; naphthyl that are connected to each other in ortho position through a chemical bond, -CH2-, -CH2-CH2-, -CH=CH-, -SO2-, -NH-, -N(alkyl)-, -O- or -S-; cycloalkyl; R6 is H, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, 5 or 6 member heteroaryl, were prepared as endothelin receptor inhibitors. Thus, Me 2-hydroxy-3-methoxy-3,3- diphenyl-propionate was prepared and reacted with 2,6-dimethoxy-4-chloro- pyrimidine, and K2CO3 at 100 °C in DMF to give Me 2-(2,6-dimethoxy-pyrimidin-4-yl-oxy)-3-methoxy-3,3-diphenyl-propionate. I bound to endothelin ETA receptors with $K_i = 0.038 - 3.3 \mu\text{M}$.

MSTR 1




G1 = tetrazolyl
 G40 = Ph (opt. substd. by 1 or more G41)
 G41 = halo
 G44 = O
 G45 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G46)
 G46 = halo / Ph (opt. substd. by 1 or more G51)
 Patent location: claim 1
 Note: additional ring formation also claimed

L89 ANSWER 3 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 146:477108 MARPAT Full-text
 TITLE: Preparation of dialkylpyridoazines as agricultural fungicides
 INVENTOR(S): Dietz, Jochen; Grammenos, Wassilios; Huenger, Udo; Lohmann, Jan Klaas; Renner, Jens; Rheinheimer, Joachim
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 51pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
DE 102005051514	A1	20070503	DE 2005-102005051514	20051026
PRIORITY APPLN. INFO.:			DE 2005-102005051514	
			20051026	

GI

10/566911



AB Title compds. (I; R1 = (substituted) alkyl, alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, cycloalkyl, Ph, phenylalkyl, alkenyl, alkynyl; R2 = (substituted) alkyl, alkenyl, alkynyl; W, X, Y, Z = ≤ 3 N, CR3; R3 = H, halo, alkyl, alkoxy], were prepared for control of plant pathogenic fungi (no data).

MSTR 1



G1 = 127



G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)

G3 = F

G13 = alkenylene <containing 2-12 C>
(opt. substd. by (1-3) G2)

G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)

Patent location: claim 1

Note: also incorporates claim 8, structures 5a and 6a

MSTR 3




G1 = 127



10/566911

G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)
 G3 = F
 G13 = alkenylene <containing 2-12 C>
 (opt. substd. by (1-3) G2)
 G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)
 Patent location: claim 5

MSFR 4



G1 = 127



G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)
 G3 = F
 G13 = alkenylene <containing 2-12 C>
 (opt. substd. by (1-3) G2)
 G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)
 Patent location: claim 5

MSFR 5



G1 = 127



G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)
 G3 = F
 G13 = alkenylene <containing 2-12 C>
 (opt. substd. by (1-3) G2)
 G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)
 Patent location: claim 5

MSFR 6

10/566911



G1 = 127



G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)


G3 = F

G13 = alkenylene <containing 2-12 C>
(opt. substd. by (1-3) G2)

G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)

Patent location: claim 8

MSTP 10



G1 = 127



G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)


G3 = F

G13 = alkenylene <containing 2-12 C>
(opt. substd. by (1-3) G2)

G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)

Patent location: claim 8

MSTP 12



G1 = 127

1943-0-G15

G2 = F / CN / OH / Ph (opt. substd. by (1-4) G3)

G3 = F

G13 = alkenylene <containing 2-12 C>
(opt. substd. by (1-3) G2)

G15 = alkyl <containing 1-6 C> (opt. substd. by (1-3) G2)

Patent location: claim 8

L89 ANSWER 4 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 145:418786 MARPAT Full-textTITLE: Substituted benzylamines as CYP2A inhibitors and their
preparation and use in treatment of nicotine
dependence

INVENTOR(S): Ghosheh, Omar; Raymond, Jeff

PATENT ASSIGNEE(S): Inflazyme Pharmaceuticals Ltd., Can.; Roth, Carol, J.

SOURCE: PCT Int. Appl., 68pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108149	A2	20061012	WO 2006-US13081	20060406
WO 2006108149	A3	20071122		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1871357	A2	20080102	EP 2006-740741	20060406
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			

PRIORITY APPLN. INFO.:	US 2005-669038P	20050406
	WO 2006-US13081	20060406

G1



I



II

AB This invention is directed to substituted benzylamines of formula I which are useful as inhibitors of the CYP2A6 enzyme. Pharmaceutical compns. comprising the compds. and methods of using the compds. to treat nicotine dependence are also disclosed. Compds. of formula I wherein R1 and R2 are independently H, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted C1-30 alkyl; R1R2 together with the N they are attached may form an (un)substituted heterocyclyl; R3 is X, (un)substituted C1-30 (halo)alkyl, NO2, carboxy, SO2R, and SO2NR2; R4 is H, X, (un)substituted C1-30 (halo)alkyl, OR, SR, NR2; R2R4 together with the N they are attached to may form an (un)substituted fused heterocycle; numerals 1 - 7 is carbon atoms; numerals 2, 3 and 5 are independently optionally substituted with X, R, NR2 and OR; numeral 7 is optionally substituted with =O, =CR2, =C=CR2, CR2(CR2)n and O(CR2)nO; X is F, Br, Cl and I; R is H and C1-30 organic moiety; and their stereoisomers, mixts. of stereoisomers, pharmaceutically acceptable salts, solvates, and prodrugs thereof are claimed. Example compound II was prepared by amidation of 3-trifluoromethylbenzoyl chloride with cyclopentylamine; the resulting N-cyclopentyl-3-trifluoromethylbenzamide underwent reduction to give compound II. All the invention compds. were evaluated for their CYP2A inhibitory activity. The most potent compds. of the invention showed greater than 98% inhibition.


MSTR 1



G3 = F
G5 = F
G6 = 93



G9 = carbon chain <containing 1-30 C,
0 or more double bonds> (opt. substd. by G26)
G13 = 2-10 3-41 1-43 6-42



G20 = OH / 99



G26 = F / Ph

Patent location:

Note:

claim 1

or mixtures or pharmaceutically acceptable salts, solvates, and prodrugs, or pharmaceutically acceptable carriers, diluents, or excipients and stereoisomers

Stereochemistry:

L89 ANSWER 5 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:

144:211234 MARPAT Full-text

TITLE:

Chemoenzymic process for synthesis of of cis-configured 3-hydroxycyclohexane carboxylic acid derivative enantiomers

INVENTOR(S):

Holla, Wolfgang; Keil, Stefanie; Tappertzhofen, Christoph

PATENT ASSIGNEE(S):

Sanofi-Aventis Deutschland GmbH, Germany

SOURCE:

PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015716	A2	20060216	WO 2005-EP8058	20050723
WO 2006015716	A3	20060622		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004038403	A1	20060223	DE 2004-10200403840320040807	
DE 102004038403	B4	20060831		
AU 2005270447	A1	20060216	AU 2005-270447	20050723
CA 2576080	A1	20060216	CA 2005-2576080	20050723
CN 1989253	A	20070627	CN 2005-80025307	20050723
EP 1805316	A2	20070711	EP 2005-778085	20050723
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

10/566911


IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2008509102 T 20080327 JP 2007-524225 20050723
MX 200700996 A 20070416 MX 2007-996 20070125
US 20070197788 A1 20070823 US 2007-669545 20070131
KR 2007041564 A 20070418 KR 2007-702917 20070206
IN 2007CN00548 A 20070824 IN 2007-CN548 20070207
PRIORITY APPLN. INFO.: DE 2004-10200403840320040807
WO 2005-EP8058 20050723

AB The invention relates to a method for producing chiral, non-racemic, cis-configured cyclohexanols or cyclohexanol derivs. by means of enzyme catalyzed kinetic resolution of racemates.


MSTR 3

G8—G1

G8 = 113



G11 = 117



G12 = F / CF3 / CN / Ph (opt. substd. by (1-3) G14) /
alkoxycarbonyl <containing 1-4 C>
(opt. substd. by (1-3) G14) / alkenyloxycarbonyl
<containing 2-4 C> (opt. substd. by (1-3) G14)
G14 = F
G15 = carbon chain <containing 1-14 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by 1 or more G12)

Patent location:

claim 1

Note:

additional oxygen interruptions of Ak in G15 also
claimed

L89 ANSWER 6 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 143:78086 MARPAT Full-text


TITLE: Preparation of urea/carbamate derivatives as
inhibitors of coagulation factor Xa for treatment of
thromboembolic disorders

INVENTOR(S): Cezanne, Bertram; Dorsch, Dieter; Mederski, Werner;

PATENT ASSIGNEE(S): Tsaklakidis, Christos; Gleitz, Johannes
 SOURCE: Merck Patent G.m.b.H., Germany
 PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056528	A1	20050623	WO 2004-EP13202	20041119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10358539	A1	20050707	DE 2003-10358539	20031215
AU 2004296956	A1	20050623	AU 2004-296956	20041119
CA 2549548	A1	20050623	CA 2004-2549548	20041119
EP 1694643	A1	20060830	EP 2004-820053	20041119
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1890216	A	20070103	CN 2004-80036500	20041119
BR 2004017153	A	20070306	BR 2004-17153	20041119
JP 2007513987	T	20070531	JP 2006-544246	20041119
IN 2006KN01578	A	20070504	IN 2006-KN1578	20060608
MX 2006PA06593	A	20060731	MX 2006-PA6593	20060609
US 20070123509	A1	20070531	US 2006-582850	20060614
PRIORITY APPLN. INFO.:			DE 2003-10358539	20031215
			WO 2004-EP13202	20041119


OTHER SOURCE(S): CASREACT 143:78086
 GI



AB Title compds. I [D = halo, alkoxy, etc.; X = amino, O; Y = O, S, amino, etc.; R1 = H, aryl, heteroaryl, etc.; E = CH, N; Z, Z' = acyl, etc.; Q = O, amino, acyl, etc.; R4-4' = A, OH, alkoxy; T = (hetero)cyclyl, etc.] are prepared. For instance, (R)-N-(4-chlorophenyl)-N'-[2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-1-phenylethyl]urea (II) is prepared in 3 steps from 1-methyl-4,4'-bipiperidiny, (R)-N-(tert-butoxycarbonyl)phenylglycine and 4-chlorophenylisocyanate. II has IC50 = 6 x 10⁻⁹ M for Factor Xa. I are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or the treatment of thromboembolic diseases and for treating tumors.

10/566911

FIG. 1



G3 = O
 G4 = Ph (opt. substd. by G34)
 G9 = (1-4) CH2
 G10 = (0-4) CH2
 G11 = N
 G12 = Ph (opt. substd. by G30)
 G19 = carbon chain <containing 1 or more C,
 0 or more double bonds, no triple bonds>
 (opt. substd. by 1 or more G20)
 G20 = F / Ph
 G30 = 73




G33 = 88-6 90-33



G34 = F
 G41 = 301



G42 = 4



Patent location:

Note: claim 1
 Note: also incorporates claim 22, formulae II and IV
 Note: substitution is restricted
 Note: or pharmaceutically acceptable salts, solvates, and


derivatives
 Note: additional substitution also claimed
 Stereochemistry: and stereoisomers and derivatives

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 7 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 143:26591 MARPAT Full-text
 TITLE: Preparation of benzoxazoles or benzothiazoles as fungicides
 INVENTOR(S): Hara, Yoshihiko; Sano, Hiroshi; Haramoto, Masanori
 PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 40 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 2005145840	A	20050609	JP 2003-382721	20031112
PRIORITY APPLN. INFO.:			JP 2003-382721	20031112

GI



AB Title compds. I [R1 = H, C1-4 alkyl, OH, etc.; R2 = AB, YCOZ; A = single bond, (substituted) C1-6 alkylene; B = (substituted) Ph, (substituted) naphthyl, etc.; Y = (substituted) C1-6 alkylene; Z = OR3, NR3R4; R3 = (substituted) C1-16 alkyl, (substituted) C3-10 cycloalkyl, etc.; R2R3 may form ring; X1, X2 = O, S; substituents for A, B, Y, and R3 are given] are prepared Thus, N-(1-ethyloxycarbonyl-2,2-dimethylpropyl)-2-hydroxy-3- nitrobenzamide was reduced over Pd/C and condensed with tri-Et orthoformate to give 95% I (R1 = H, R2 = 1-ethyloxycarbonyl-2,2- dimethylpropyl, X1 = X2 = O).

MSTR 1



10/566911

G3 = 17

₁G11-C(=O)-G15

G4 = F
 G11 = alkylene <containing 1-6 C>
 (opt. substd. by 1 or more G12)
 G12 = alkyl <containing 1-12 C> /
 alkenyl <containing 2-8 C> (opt. substd. by 1 or more G6) /
 alkynyl <containing 2-8 C> (opt. substd. by 1 or more G6) /
 alkyl <containing 1-8 C> (substd. by 1 or more G13) /
 alkoxycarbonyl <containing 1-8 C> /
 Ph (opt. substd. by 1 or more G4)
 G13 = alkoxycarbonyl <containing 1-8 C> /
 alkylaminocarbonyl <containing 1-8 C>
 G15 = 20



₂G20-G16

G16 = alkenyl <containing 2-8 C>
 (opt. substd. by 1 or more G18)
 G18 = Ph (opt. substd.) / F
 G20 = O
 Patent location: claim 1

L89 ANSWER 8 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 142:240437 MARPAT Full-text
 TITLE: Preparation of triazolyimethanol derivatives as
 antifungal agents
 INVENTOR(S): Kim, Bum Tae; Min, Yong Ki; Lee, Yeon Soo; Park, No
 Kyun; Kim, Woo Jung
 PATENT ASSIGNEE(S): Korea Research Institute of Chemical Technology, S.
 Korea
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014583	A1	20050217	WO 2004-KR1996	20040809
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

SN, TD, TG
 KR 2005017962 A 20050223 KR 2003-55590 20030812
 EP 1654254 A1 20060510 EP 2004-748524 20040809
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 JP 2007502268 T 20070208 JP 2006-523125 20040809
 US 20080027117 A1 20080131 US 2006-566911 20060203
 PRIORITY APPLN. INFO.: KR 2003-55590 20030812
 WO 2004-KR1996 20040809
 OTHER SOURCE(S): CASREACT 142:240437
 GI



AB Title compds. represented by the formula I [wherein A = O, 1,2,4-triazolyl-PhO-, 1,2,4-triazolone-3-yl-PhO-, imidazolone-1-yl-PhO, imidazolinone-1-yl-PhO-; R = H or CF₃; R' = H or alkyl; X = H, halo, (halo)alkyl,alkoxy, 3,4-dioxyalkylene; and pharmaceutically acceptable salts, isomers or esters thereof] were prepared as antifungal agents for the treatment of humans or animals. For example, II was given in a multi-step synthesis starting from the reaction of Me (R)-lactate with morpholine. I showed antifungal activity in vivo against a wide spectrum of pathogenic fungi, such as ATCC 10231 and MYA-573, and low toxicity in oral administration.

MSTR 1



G1 = O

Patent location:

claim 1

Note:

or pharmaceutically acceptable salts or esters

Stereochemistry:

or isomers

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 9 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 142:225780 MARPAT Full-textTITLE: Pharmaceutical compositions containing amino alcohol
derivatives or phosphonic acid derivatives for use as
immunosuppressants

INVENTOR(S):

Nishi, Takehide; Shimozato, Ryuichi; Nara, Futoshi;
Miyazaki, Shojiro

PATENT ASSIGNEE(S):

Sankyo Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 253 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:


Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005041867	A	20050217	JP 2004-197492	20040705
US 20070105933	A1	20070510	US 2006-636776	20061211
PRIORITY APPLN. INFO.:			JP 2003-193599	20030708
			JP 2002-4456	20020111
			JP 2002-4484	20020111
			WO 2003-JP136	20030109
			JP 2003-4599	20030110
			JP 2004-197492	20040705
			US 2004-889657	20040712

GI



AB The invention relates to pharmaceutical compns. for use as immunosuppressants for treatment and/or prevention of rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, psoriasis vulgaris, atopic dermatitis, insulin-dependent diabetes, glomerulonephritis, and graft rejection, etc., characterized by containing alc. derivs. or phosphonic acid derivs. I (R1, R2 = H, lower alkyl, an amino-protecting group; R3 = H, lower alkyl, a hydroxy-protecting group; R4 = lower alkyl; n = 1-6; X = O, (un)substituted N; Y = ethylene, vinylene, ethynylene, COCH2, CH(OH)CH2, (un)substituted C6-10 arylene; Z = a single bond, C1-10 (un)substituted alkylene optionally containing O or S in or at terminus of the carbon chain; R5 = H, each (un)substituted C3-10 cycloalkyl, C6-10 aryl, 5-7-membered heterocyclyl containing 1-3 of S, O, and/or N; R6, R7 = H, halo, lower alkyl, lower haloalkyl, lower alkoxy, lower alkylthio, CO2H, lower alkoxycarbonyl, HO, lower aliphatic acyl, NH2, mono- or di(lower alkyl) amino, lower aliphatic acylamino, cyano, NO2; provided that when R5 is hydrogen, then Z is branched or substituted C1-10 alkylene or C1-10 alkylene containing O or S in or at terminus of the carbon chain], pharmacol. acceptable salts thereof or pharmacol. acceptable esters thereof. For example, a compound (2R)-2-amino-2-methyl-4-[5-(5-cyclohexylpent-1-ynyl)furan-2-yl]butan-1-ol was prepared, and its effect on adjuvant arthritis rats was examined

MSTR 1



G7 = 18-4 19-6 / 30-4 32-6 / 38-4 40-6 /
43-4 44-6 / 45-4 46-6

1G8-G13 3G14-G15-G16 3G19-G15-G18 4G20-G15 4G21-G25

G11 = carbon chain <containing 1-7 C>

G12 = F / alkyl <containing 1-6 C>
(opt. substd. by 1 or more G10) / CO2H /
alkoxycarbonyl <containing 1-6 C> / OH / 25 / CN

2G(0)-G11

G13 = 35-18 37-6 / 41-18 42-6

3G17-G15-G18 4G16-G15

G15 = O

10/566911

G18 = alkylene <containing 1-9 C>
(opt. substd. by (1-3) G12)
G21 = phenylene (opt. substd. by (1-3) G39)
G22 = Ph
G25 = 92-45 94-6 / 95-45 96-6


9218-15-9 916-915

G39 = F
Patent location: claim 1
Note: or pharmacologically acceptable salts or esters
Note: additional heteroatom interruptions also claimed
Note: substitution is restricted
Note: also incorporates claim 4 and 7

L89 ANSWER 10 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 140:406954 MARPAT [Full-text](#)
TITLE: Preparation of thienylalkyl phosphates or
(thienylalkyl)phosphonic acids as immunosuppressants
with low toxicity
INVENTOR(S): Nishi, Takehide; Shimozato, Ryuichi; Nara, Futoshi
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 199 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004137208	A	20040513	JP 2002-304196	20021018
PRIORITY APPLN. INFO.:			JP 2002-304196	20021018

GI




AB The title compds. I [R1, R2 = H, lower aliphatic acyl, lower alkoxycarbonyl; R3, R8 = H, protecting group; R4 = H, lower (hydroxy)alkyl; n = 1-6; X = ethylene, vinylene, ethynylene, C6-10 arylene, etc.; Y = bond, C1-10 (un)substituted alkylene; Z = O, CH2; R5 = H, (un)substituted C3-10 cycloalkyl, (un)substituted C6-10 aryl, (un)substituted heterocyclyl; when R5 = H, then Y ≠ bond; R6, R7 = H, halo, lower (halo)alkyl, lower alkoxy, OH, cyano, NO2, etc.], their pharmacol. acceptable salts, or esters are prepared Thus, treatment of bis(allyl) mono[(2R)-tert- butoxycarbonylamino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butyl] phosphate with

10/566911

tetrakis(triphenylphosphine)palladium gave 69% mono[(2R)-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butyl] phosphate, which inhibited host vs. graft reaction in rats with ID50 value of 0.0878 mg/kg.

NOTE 1



G7 = 18-4 19-6 / 30-4 32-6 / 38-4 40-6 /
43-4 44-6 / 45-4 46-6

1~~6~~8-~~6~~13 3~~6~~14-~~3~~415-~~2~~16 3~~6~~19-G15-~~4~~630 4~~6~~20-~~4~~15 4~~6~~21-~~4~~625

G11 = carbon chain <containing 1-7 C>

G12 = F / alkyl <containing 1-6 C>
(opt. substd. by 1 or more G10) / CO2H /
alkoxycarbonyl <containing 1-6 C> / OH / 25 / CN

2~~5~~(0)-G11

G13 = 35-18 37-6 / 41-18 42-6

3~~6~~17-G15-~~3~~618 4~~6~~27-~~4~~615

G15 = O

G18 = alkylene <containing 1-9 C>
(opt. substd. by (1-3) G12)

G21 = phenylene (opt. substd. by (1-3) G39)

G22 = Ph

G25 = 92-45 94-6 / 95-45 96-6

9~~2~~18-G15-~~9~~631 9~~6~~28-~~9~~615

G31 = alkylene <containing 1-10 C>
(opt. substd. by (1-3) G12)

G39 = F

Patent location: claim 1

Note: or pharmacologically acceptable salts or esters

Note: additional heteroatom interruptions also claimed

10/566911

Note: substitution is restricted
 Note: also incorporates claim 7

L89 ANSWER 11 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 139:197921 MARPAT Full-text

TITLE: Diol esters useful in preparation of a catalyst for olefin polymerization, process for preparing the same and use thereof

INVENTOR(S): Gao, Mingzhi; Wang, Jun; Li, Changxiu; Li, Jiyu; Li, Tianyi; Li, Xianzhong; Ma, Jing; Xing, Lingyan; Liu, Haitao

PATENT ASSIGNEE(S): China Petroleum and Chemical Corp., Peop. Rep. China; Beijing Research Institute of Chemical Industry; et al.

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068723	A1	20030821	WO 2003-CN111	20030130
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CN 1436766	A	20030820	CN 2002-100896	20020207
AU 2003245432	A1	20030904	AU 2003-245432	20030130
EP 1478617	A1	20041124	EP 2003-739422	20030130
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005517702	T	20050616	JP 2003-567858	20030130
US 20050096389	A1	20050505	US 2004-503119	20041201
PRIORITY APPLN. INFO.:			CN 2002-100896	20020207
			WO 2003-CN111	20030130

AB The present application relates to diol ester compds. R1CO-O-CR3R4-A-CR5R6-O-CO-R2 (I; e.g. 1,2-ethylene glycol dibenzoate) wherein, R1 and R2 groups, which may be identical or different, can be (un)substituted hydrocarbyl having 1-20 C atoms, R3-R6 groups, which may be identical or different, can be H, halogen or (un)substituted hydrocarbyl having 1-20 C atoms, R1-R6 groups optionally contain ≥ 1 hetero-atoms replacing C, H atom or the both, said heteroatom = N, O, S, Si, P and halogen atom, two or more of R3-R6 groups can be linked to form saturated or unsatd. monocyclic or polycyclic ring; A is a single bond or bivalent linking group with chain length between two free radicals being 1-10 atoms, wherein said bivalent linking aliphatic, alicyclic and aromatic bivalent radicals, and can carry C1-C20 linear or branched substituents; ≥ 1 of C atom and/or H atom on the substituents can be replaced by a hetero-atom N, O, S, Si, P, and halogen atom, and two or more said substituents on the linking group as well as above-mentioned R3-R6 groups can be linked to form saturated or unsatd. monocyclic or polycyclic ring. I can be used as a electron donor compound in the preparation of a catalyst for

olefin polymerization, and a catalyst with excellent general properties can be obtained. When the catalyst obtained was used in polymerization of propylene, satisfactory polymerization yield was obtained, and stereo-direction of the polymer was very high. Even if an external donor is not used, relatively high isotactic polymer can still be obtained. Hydrogen response of the catalyst is excellent, and distribution of the mol. weight of the polymer obtained is relatively wide, and these properties are desirable in the development of different grades of polymers. In addition, when the catalyst is used in the copolymn. of olefins, especially in the copolymn. of ethylene and propylene, less gel content is achieved (no data). Ninety-nine example preps. are included. For example, for preparation of 1,2-ethylene glycol dibenzoate (92 % yield), to 2.8 g (0.05 mol) 1,2-ethylene glycol was added 50 mL THF, then added 12.1ml (0.15 mol) pyridine with stirring. To the resulting homogeneous mixture was slowly added 14.5 mL (0.125 mol) benzoyl chloride, and the mixture was stirred for 1 h at room temperature, then heated refluxing for 4 h. For preparation of the solid catalyst components, to a reactor which was completely replaced with high pure N₂ were added successively 4.8 g MgCl₂, 95 mL toluene, 4 mL epoxychloropropane, and 12.5 mL tri-Bu phosphate. The mixture was heated to 50° with stirring and held at the temperature for 2.5 h to dissolve the solid completely, then 1.4 g phthalic anhydride was added and the temperature was held for 1 h further. The solution was cooled to <-25° and added dropwise were 56 mL TiCl₄ over 1 h, then heating was slowly done to 80°; solid was precipitated gradually during the heating. To the system were added 6 mmol of diol ester and the reaction was held at the temperature with stirring for a further 1 h. After removing the supernatant, to the residue was added 70 mL toluene and the supernatant was removed again after mixing completely; the washing procedure was repeated twice. The resulting solid precipitate was treated with 60 mL toluene and 40 mL TiCl₄ at 100° for 2 h, and after removing the supernatant, the residue was treated with 60 mL toluene and 40 mL TiCl₄ at 100° for 2 h again. After removing the supernatant, the residue was washed with 60 mL toluene under boiling state for three times, 60 mL hexane under boiling state for two times, 60 mL hexane at normal temperature for two times to yield the solid catalyst components. The catalyst components obtained above were used in the polymerization of propylene. To a 5 L stainless steel autoclave, which had been replaced with propylene gas completely, were added 2.5 mmol AlEt₃, 0.1 mmol cyclohexylmethyldimethoxysilane, .apprx.10 mg of the solid catalyst component prepared as above, and 1.2 L H₂, followed by introduction of 2.3 L liquid propylene. The reactor was heated to 70°, and the polymerization was performed at that temperature and autogenous pressure for 1 h. In one case using 2,4-pentanedio diol bis(p-butylbenzoate) (22.1 weight % diol ester and 3.1 weight % Ti), 64.2 kg polypropylene/ g catalyst was obtained with 98.6 % isotacticity and a 9.7 mol. weight distribution.

MSTR 1



G2 = 17-3 19-5




10/566911

G5 = F / Ph (opt. substd. by G8)
G8 = F
G9 = carbon chain <containing 1 or more C>
(opt. substd. by G5) / 47



G10 = O
Patent location: claim 1

MS TP 1



G2 = 17-3 19-5



G5 = F / Ph (opt. substd. by G8)
G8 = F
G9 = carbon chain <containing 1 or more C>
(opt. substd. by G5) / 47



G10 = O
Patent location: claim 1

MS TP 2



G2 = 17-3 19-5



10/566911

G5 = F / Ph (opt. substd. by G8)
 G8 = F
 G9 = carbon chain <containing 1 or more C>
 (opt. substd. by G5) / 47

G5—G—G5

G10 = O

Patent location: claim 25

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 12 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 139:133462 MARPAT Full-text

TITLE: Preparation of 2-amino-4-(2-furanyl or 2-pyrrolyl)butanol or 3-amino-5-(2-furanyl or 2-pyrrolyl)pentylphosphonic acid derivatives as immunosuppressants

INVENTOR(S): Nishi, Takahide; Shimozato, Takaichi; Nara, Futoshi; Miyazaki, Shojiro

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 592 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059880	A1	20030724	WO 2003-JP136	20030109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473461	A1	20030724	CA 2003-2473461	20030109
AU 2003202495	A1	20030730	AU 2003-202495	20030109
BR 2003006811	A	20041026	BR 2003-6811	20030109
EP 1471054	A1	20041027	EP 2003-701048	20030109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1630635	A	20050622	CN 2003-805925	20030109
NZ 533994	A	20061027	NZ 2003-533994	20030109
JP 2003267950	A	20030925	JP 2003-4599	20030110
IN 2004KN00962	A	20060428	IN 2004-KN962	20040708
MX 2004PA06709	A	20041004	MX 2004-PA6709	20040709
US 20050043386	A1	20050224	US 2004-889657	20040712
US 7199150	B2	20070403		
NO 2004003319	A	20041005	NO 2004-3319	20040810
ZA 2004006333	A	20051020	ZA 2004-6333	20040810

10/566911

US 20070105933 A1 20070510
 US 20070142335 A1 20070621
 PRIORITY APPLN. INFO.:

US 2006-636776 20061211
 US 2007-651205 20070109
 JP 2002-4456 20020111
 JP 2002-4484 20020111
 WO 2003-JP136 20030109
 JP 2003-4599 20030110
 JP 2004-197492 20040705
 US 2004-889657 20040712

GI




AB Amino alc. derivs. or phosphonic acid derivs., pharmacol. acceptable salts thereof or pharmacol. acceptable esters thereof (I) [R1, R2 = H, lower alkyl, an amino-protecting group; R3 = H, lower alkyl, a hydroxy-protecting group; R4 = lower alkyl; n = an integer of 1 to 6; X = O, (un)substituted; Y = ethylene, vinylene, ethynylene, COCH2, CH(OH)CH2, (un)substituted C6-10 arylene; Z = a single bond, C1-10 (un)substituted alkylene optionally containing O or S in or at terminus of the carbon chain; R5 = H, each (un)substituted C3-10 cycloalkyl, C6-10 aryl, 5- o 7-membered heterocyclyl containing 1-3 of S, O, and/or N; R6, R7 = H, halo, lower alkyl, lower haloalkyl, lower alkoxy, lower alkylthio, CO2H, lower alkoxy carbonyl, HO, lower aliphatic acyl, NH2, mono- or di(lower alkyl) amino, lower aliphatic acylamino, cyano, NO2; provided that when R5 is hydrogen, then Z is branched or substituted C1-10 alkylene or C1-10 alkylene containing O or S in or at terminus of the carbon chain] are prepared. These compds. possess an excellent immunosuppressive activity and are useful for the prevention or treatment of autoimmune diseases, chronic articular rheumatism, or organ transplant rejection. They are also used in combination with another immunosuppressant selected from (1) drugs inhibiting cellular signal related to cytokine expression of T cell, (2) drugs inhibiting nucleoside synthesis in immune cells, (3) drugs inhibiting the effect of cytokines against immune cells and possessing antirheumatic effect, (4) alkylating agents causing cell death by destruction of DNA chain or synthesis disorder of DNA, (5) antimetabolites inhibiting the nucleic acid metabolism by inhibiting the folic acid production, (6) protein preps. possessing TNF α inhibitory activity, (7) steroid hormones forming complexes by binding to cellular steroid receptors and exhibiting an immunosuppressive activity through proteins synthesized by binding to the reactive site of chromosome, (8) substances inhibiting the production of prostaglandins, and/or (9) nonsteroidal antiinflammatory agents antagonizing prostaglandins. Thus, 4.23 g (2R)-1-acetoxy-2-acetylamino-2-methyl-4-(1-methylpyrrol-2-yl)butane was dissolved in 100 mL toluene, treated with a solution of 9.41 g 4-4-dimethylaminopyridine and 7.92 g 5-phenylvaleryl chloride in 50 mL toluene, and stirred at 110° for 48 h to give 4.03 g (2R)-1-acetoxy-2-acetylamino-2-methyl-4-[1-methyl-5-[5-phenyl-1-(5-phenylpentanoyloxy)pent-1-enyl]pyrrol-2-yl]butane (45% yield) which (4.027 g) was dissolved in a mixture of 14 mL THF and 14 mL MeOH, treated with 14 mL H2O and 2.88 g LiOH.H2O, and stirred at 50° for 4 h to give, after workup, (2R)-2-amino-2-methyl-4-[1-methyl-5-(5-phenylpentanoyl)pyrrol-2-yl]butan-1-ol (II). II.HCl inhibited host vs. graft reaction of WKAH/Hkm or Lewis rat spleen cells transplanted s.c. in Lewis rat

10/566911

rear soles with ID50 of 0.013 mg/kg. A tablet formulation 2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butan-1-ol maleate was described.

NCTR 1



G7 = 18-4 19-6 / 30-4 32-6 / 38-4 40-6 /
43-4 44-6 / 45-4 46-6

1G8-G13 3G14-G15-G16 3G19-G15-G18 4G20-G15 4G21-G25

G11 = carbon chain <containing 1-7 C>
G12 = F / alkyl <containing 1-6 C>
(opt. substd. by 1 or more G10) / CO2H /
alkoxycarbonyl <containing 1-6 C> / OH / 25 / CN

2G(0)-G11

G13 = 35-18 37-6 / 41-18 42-6

3G17-G15-G18 4G16-G15

G15 = O
G18 = alkylene <containing 1-9 C>
(opt. substd. by (1-3) G12)
G21 = phenylene (opt. substd. by (1-3) G39)
G22 = Ph
G25 = 92-45 94-6 / 95-45 96-6

9G18-G15-G18 9G16-G15

G39 = F

Patent location:

claim 1

Note: or pharmacologically acceptable salts or esters
Note: additional heteroatom interruptions also claimed
Note: substitution is restricted
Note: also incorporates claim 4 and 7

10/566911

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 13 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 139:133350 MARPAT Full-textTITLE: Amidoacetonitrile derivatives useful as parasiticides,
and their preparation, compositions, and useINVENTOR(S): Ducray, Pierre; Goebel, Thomas; Fruechtel, Joerg;
Bouvier, Jacques; Flum, Gabriela

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059868	A1	20030724	WO 2003-EP498	20030120
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			
RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR			
CA 2468423	A1	20030724	CA 2003-2468423	20030120
AU 2003202580	A1	20030730	AU 2003-202580	20030120
EP 1470103	A1	20041027	EP 2003-701531	20030120
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003007011	A	20041103	BR 2003-7011	20030120
CN 1602296	A	20050330	CN 2003-801730	20030120
JP 2005514453	T	20050519	JP 2003-559972	20030120
NZ 533964	A	20060224	NZ 2003-533964	20030120
ZA 2004003851	A	20050810	ZA 2004-3851	20040519
US 20050059736	A1	20050317	US 2004-501495	20040714
US 7153814	B2	20061226		
IN 2004CN01580	A	20060224	IN 2004-CN1580	20040716
MX 2004PA07048	A	20041011	MX 2004-PA7048	20040721
PRIORITY APPLN. INFO.:			CH 2002-97	20020121
			WO 2003-EP498	20030120


GI



AB The invention relates to compds. I [in which R1 = H, alkyl, haloalkyl, cyanoalkyl, alkoxyethyl, or benzyl; R2, R3, R4, R5, R6 = H, halo, unsubstituted or mono- or polyhalogenated alk(en/yn)yl, (un)substituted alkoxy, haloalkoxy, cycloalkyl, or phenyl; or R2R3 = C2-6 alkylene; R7 = (un)substituted cycloalkoxy, cycloalkylthio, or [cycloalkyl](R9)N, in which the substituents are halo, alkyl, hetaryl, or hetaryloxy; R8 = halo, NO2, cyano, (halo)alk(en)yl, (halo)alkoxy, alkynyl, cycloalkyl, alkenyloxy, haloalkenyloxy, alkylthio, haloalkylthio, alkylsulfonyloxy, haloalkylsulfonyloxy, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkenylthio, haloalkenylthio, (un)substituted Ph, PhO, PhNH, PhCO, PhCH(OH), etc.; or R7R8 = C3-5 alkylene; Ar = (un)substituted Ph, hetaryl, naphthyl, or quinolyl (substituents as given for R7, R8); R9 = H, alkyl, haloalkyl, allyl, alkoxyethyl, or COR10; R10 = alkyl, haloalkyl, or alkoxyethyl; W = O, S, SO2, or N(R11); R11 = H or alkyl; p = 1, 2, 3, or 4; q = 0, 1, 2, 3, or 4; and n = 0-2; in which, if R7 = hetaryloxy, the hetaryl group in R7 is other than pyridyl; including enantiomers]. Compds. I have advantageous pesticidal properties, and are particularly suitable for controlling parasites in warm-blooded animals. A list of 120 possible specific compds. I is given, and one of these (II) is prepared and claimed per se. Claims include pharmaceutical and agrochem. compns., as well as use of I to control parasites. Thus, II was prepared in 6 steps: (1) Pd-catalyzed amination of 2-bromo-4,5-difluoroanisole with cyclopropylamine; (2) N-methylation of the secondary amine product using NaH and MeI in DMF; (3) demethylation of the anisole methoxy group using BBr3; (4) etherification of the resultant phenol with chloroacetone using K2CO3 and KI; (5) aminocyanation of the ketone with NaCN and NH4Cl in aqueous NH3; and (6) amidation of the amino group with 4-(CF3O)C6H4COCl and DMAP in CH2Cl2. II was active against the nematodes *Trichostrongylus colubriformis* and *Haemonchus contortus* in Mongolian gerbils, by peroral administration at doses in the range of 0.01 to 100 mg/kg. Tests for action against various ecto- and endo-parasitic insects and acarids, namely *Lucilia sericata*, *Boophilus microplus*, *Amblyomma hebraeum*, *Dermanyssus gallinae*, and *Musca domestica*, are described. Preferred formulations include granules, tablets, boluses, injectables, and pour-ons.



G3 = 14-3 17-5



G7 = alkylene <containing 1-4 C, unbranched>
(opt. substd. by 1 or more G20)
G8 = O
G9 = alkylene <containing 1-4 C>
(opt. substd. by 1 or more G20)
G13 = F
G20 = F / carbon chain <containing 1 or more C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by 1 or more G4) /
alkoxy <containing 1 or more C>
(opt. substd. by 1 or more G4) / Ph (opt. substd.)
G21 = Ph (opt. substd. by 1 or more G13)
Patent location: claim 1
Note: also incorporates claim 8

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L89 ANSWER 14 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 138:304067 MARPAT Full-text
TITLE: Preparation of 1-cyano-1-methyl-2-phenoxyethyl
benzoates and phenylcarbamates for controlling
parasites on warm-blooded animals
INVENTOR(S): Goebel, Thomas; Ducray, Pierre
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031393	A2	20030417	WO 2002-EP11087	20021002
WO 2003031393	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU,
LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG,
SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW


RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR
 CA 2455999 A1 20030417 CA 2002-2455999 20021002
 AU 2002349321 A1 20030422 AU 2002-349321 20021002
 EP 1434760 A2 20040707 EP 2002-781206 20021002
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 BR 2002013125 A 20040921 BR 2002-13125 20021002
 CN 1545500 A 20041110 CN 2002-816448 20021002
 JP 2005531489 T 20051020 JP 2003-534377 20021002
 NZ 531640 A 20061130 NZ 2002-531640 20021002
 RU 2296747 C2 20070410 RU 2004-114242 20021002
 ZA 2004000562 A 20050407 ZA 2004-562 20040126
 US 20040236137 A1 20041125 US 2004-487167 20040217
 US 7262209 B2 20070828
 MX 2004PA03158 A 20040727 MX 2004-PA3158 20040402
 IN 2004CN00683 A 20060113 IN 2004-CN683 20040402
 CH 2001-1829 20011004
 WO 2002-EP11087 20021002
 PRIORITY APPLN. INFO.:

GI



AB The title compds. [I; Ar1, Ar2 = (un)substituted Ph, NHPh, CPh, etc.; R4-R8 = H, halo, alkyl, etc.; W = O, S, SO2, NR9 (wherein R9 = H, alkyl); X = O, S, NR10 (R10 = H, alkyl, haloalkyl, allyl, alkoxyethyl); a = 1-4; b = 0-4] which are especially suitable for controlling parasites on warm-blooded animals, were prepared. Thus, reacting 3-(2-chlorophenoxy)-2-hydroxy-2-methylpropionitrile (preparation given) with 4-trifluoromethylphenyl isocyanate in the presence of Et3N in CH2Cl2 afforded the title compound II.

MSTR 1



G8 = carbon chain <containing 2 or more C,
 0 or more double bonds, 0 or more triple bonds>
 (substd. by 1 or more G9)

10/566911

G9 = (1) CN / Ph (opt. substd. by 1 or more G11)
 G11 = F
 G12 = 35-6 36-8



3514-3615

G14 = O
 G15 = carbon chain <containing 1 or more C,
 0 or more double bonds, 0 or more triple bonds>
 (opt. substd. by 1 or more G16)
 G16 = F / Ph (opt. substd. by 1 or more G11)
 Patent location: claim 1
 Note: substitution is restricted
 Note: additional ring formation also claimed

L89 ANSWER 15 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 138:304061 MARPAT Full-text
 TITLE: Preparation of cyanoacetamides for controlling
 parasites on warm-blooded animals
 INVENTOR(S): Ducray, Pierre; Goebel, Thomas
 PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis-Erfindungen
 Verwaltungsgesellschaft m.b.H.
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031394	A1	20030417	WO 2002-EP11088	20021002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2458446	A1	20030417	CA 2002-2458446	20021002
AU 2002342791	A1	20030422	AU 2002-342791	20021002
EP 1436250	A1	20040714	EP 2002-779457	20021002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013066	A	20040928	BR 2002-13066	20021002
CN 1564809	A	20050112	CN 2002-819548	20021002
JP 2005504841	T	20050217	JP 2003-534378	20021002
NZ 531634	A	20051028	NZ 2002-531634	20021002
RU 2296119	C2	20070327	RU 2004-114240	20021002
ZA 2004001481	A	20050527	ZA 2004-1481	20040224
US 20040242913	A1	20041202	US 2004-489697	20040311
IN 2004CN00685	A	20060113	IN 2004-CN685	20040402
MX 2004PA03157	A	20060427	MX 2004-PA3157	20040402
PRIORITY APPLN. INFO.:			CH 2001-1828	20011004
			WO 2002-EP11088	20021002

GI



AB The title compds. [I; Ar1, Ar2 = (un)substituted Ph, NHPH, CPh, etc.; R4-R10, R12 = H, halo, alkyl, etc.; W = O, SOn, NR11 (wherein n = 0-2; R11 = H, alkyl); X = O, S, NR12; a = 1-4; b, c = 0-4] such as II which have advantageous pesticidal properties, were prepared. One preparation example is given but no phys. data for intermediates and final product. Table of 783 compds. I is presented (data for only five of them are given).

MSR 1



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L89 ANSWER 16 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 137:124992 MARPAT Full-text
 TITLE: Preparation of (acylamino)salicylic acids and their use as agrochemical fungicides

INVENTOR(S): Hara, Yoshihiko; Saika, Michiyuki

PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002212157	A	20020731	JP 2001-89139	20010327
PRIORITY APPLN. INFO.:			JP 2000-90870	20000329
			JP 2000-350481	20001117


GI



I

AB Title compds. I [R1 = H, C1-4 alkyl; A = (un)substituted C1-6 alkylene; X = O, NR3, CR3R4; R2 = (un)substituted C1-16 alkyl, (un)substituted C3-10 cycloalkyl, (un)substituted C2-10 alkenyl, etc.; R3, R4 = H, C1-10 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy; NR2R3 may form ring] and their salts are prepared. Thus, N-(1-n-heptyloxycarbonylethyl)-2-benzyloxy-3- nitrobenzamide was hydrogenated over Pd/C in AcOEt, filtered, evaporated, and treated with N-formylimidazole in CH2Cl2 to give 53% I (R1 = H, A = CHMe, XR2 = OC7H15-n), which showed ≥75% antifungal activity against *Venturia inaequalis*.

MSTR 1



G2 = alkylene <containing 1 or more C>
 (opt. substd. by 1 or more G3)

G3 = alkenyl <containing 2-8 C>
 (opt. substd. by 1 or more G4) /

10/566911

alkynyl <containing 2-8 C> (opt. substd. by 1 or more G4) /
 Ph (opt. substd. by 1 or more G7) / OH /
 alkoxycarbonyl <containing 1-8 C> /
 alkylaminocarbonyl <containing 1-8 C>

G7 = F
 G12 = 28

$2^6_{(0)}-G23$

G14 = alkenyl <containing 2-10 C>
 (opt. substd. by 1 or more G16)
 G16 = Ph (opt. substd. by 1 or more G7) / F
 G18 = 0
 G23 = 29

$2^6_{18}-G14$

Patent location: claim 1
 Note: or salts

L89 ANSWER 17 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 131:165311 MARPAT Full-text
 TITLE: New carboxylic acid derivatives with 5-substituted
 pyrimidine ring, their preparation and use as
 endothelin receptor antagonists
 INVENTOR(S): Amberg, Wilhelm; Jansen, Rolf; Kling, Andreas; Klinge,
 Dagmar; Riechers, Hartmut; Hergenroeder, Stefan;
 Raschack, Manfred; Unger, Liliane
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19806438	A1	19990819	DE 1998-19806438	19980217
CA 2321182	A1	19990826	CA 1999-2321182	19990205
WO 9942453	A1	19990826	WO 1999-EP776	19990205
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HR, HU, ID, IL, IN, JP, KR,				
KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US,				
AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE				
AU 9930271	A	19990906	AU 1999-30271	19990205
BR 9907911	A	20001024	BR 1999-7911	19990205
TR 200002376	T2	20001221	TR 2000-2376	19990205
EP 1066268	A1	20010110	EP 1999-911657	19990205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
SI, FI, RO				
JP 2002503726	T	20020205	JP 2000-532405	19990205

HU 2001000957	A2	20020228
TW 579376	B	20040311
ZA 9901214	A	20000816
MX 2000PA06463	A	20010219
BG 104577	A	20010330
IN 2000CN00227	A	20050304
NO 200004075	A	20000815
HR 2000000602	A1	20010630

PRIORITY APPLN. INFO.:


HU 2001-957	19990205
TW 1999-88102031	19990210
ZA 1999-1214	19990216
MX 2000-PA6463	20000629
BG 2000-104577	20000704
IN 2000-CN227	20000728
NO 2000-4075	20000815
HR 2000-602	20000913
DE 1998-19806438	19980217
WO 1999-EP776	19990205

GI



AB The title compds. [I; R1 = tetrazolyl, C(O)R; R = OR7, (substituted) N-linked 5-membered heteroarom. residue, O(CH2)pS(:O)kR8, NHSO2R9; R7 = H, cation, (substituted) C3-8 cycloalkyl, (substituted) C1-8 alkyl, (substituted) Ph, (substituted) CH2Ph, C3-6 (halo)alkenyl, C3-6 (halo)alkynyl; R8, R9 = (substituted) C1-4 alkyl, (substituted) C3-8 cycloalkyl, (substituted) C3-6 alkenyl, (substituted) C3-6 alkynyl, (substituted) Ph; k = 0-2; p = 1-4; R2, R3 = H, OH, (substituted) amino, halo, alkyl, alkenyl, alkynyl, hydroxyalkyl, haloalkyl, alkoxy, etc.; R4, R5 = (substituted) Ph, (substituted) naphthyl, C3-7 cycloalkyl, etc.; R6 = H, (substituted) C1-8 alkyl, (substituted) C3-6 alkenyl, (substituted) C3-6 alkynyl, (substituted) C3-8 cycloalkyl, (substituted) Ph, (substituted) naphthyl, (substituted) 5- or 6-membered heteroarom. residue; X = halo, C1-4 haloalkyl, OH; Z = O, S, single bond], their enantiomers, diastereomers, and physiol. compatible salts are useful as endothelin receptor antagonists for treatment of diseases associated with elevated endothelin levels, such as chronic cardiac insufficiency, restenosis, hypertension, acute or chronic kidney failure, cerebral ischemia, asthma, benign prostate hyperplasia, and prostate cancer. Thus, Me 2-hydroxy-3-methoxy-3,3-diphenylpropionate reacted with NaH and 4,6-dimethoxy-5-fluoro-2-methylsulfonylpyrimidine in DMF to produce I (R1 = CO2Me, R2 = R3 = OMe, R4 = R5 = Ph, R6 = Me, X = F, Z = O), which was saponified to the corresponding acid (R1 = CO2H) (II). II bound to endothelin ETA and ETB receptors with Ki 7.4 and 1200 nM, resp.

MSTR 1A



G1 = tetrazolyl

10/566911

G25 = Ph (opt. substd. by 1 or more G26)
 G26 = F
 G27 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G28)
 G28 = F / Ph (opt. substd. by (1-3) G29)
 G35 = O


Derivative: and physiologically acceptable salts
 Patent location: claim 1
 Note: substitution is restricted
 Note: additional ring formation also claimed
 Stereochemistry: and enantiomeric and diastereomeric forms

L89 ANSWER 18 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 130:257367 MARPAT Full-text
 TITLE: Multicomponent pharmaceutical formulations for
 treatment of vasoconstrictive disorders
 INVENTOR(S): Kirchengast, Michael; Muentner, Klaus
 PATENT ASSIGNEE(S): Knoll A.-G. Chemische Fabriken, Germany
 SOURCE: Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19743143	A1	19990401	DE 1997-19743143	19970930
CA 2304698	A1	19990408	CA 1998-2304698	19980910
CA 2304698	C	20080219		
WO 9916444	A1	19990408	WO 1998-EP5772	19980910
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9892672	A	19990423	AU 1998-92672	19980910
AU 739860	B2	20011025		
EP 1019055	A1	20000719	EP 1998-945323	19980910
EP 1019055	B1	20030507		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE, FI				
BR 9812404	A	20000919	BR 1998-12404	19980910
JP 2001517703	T	20011009	JP 2000-513580	19980910
HU 2000004590	A2	20011128	HU 2000-4590	19980910
AT 239479	T	20030515	AT 1998-945323	19980910
RU 2213577	C2	20031010	RU 2000-111500	19980910
ES 2199461	T3	20040216	ES 1998-945323	19980910
CZ 298745	B6	20080116	CZ 2000-1081	19980910
MX 200002654	A	20001211	MX 2000-2654	20000316
US 6352992	B1	20020305	US 2000-508989	20000320
NO 2000001634	A	20000329	NO 2000-1634	20000329
NO 319048	B1	20050606		
HK 1032355	A1	20050304	HK 2001-102973	20010425
PRIORITY APPLN. INFO.:				
			DE 1997-19743143	19970930
			WO 1998-EP5772	19980910

GI



AB Novel combinations of an endothelin antagonist and a β -receptor blocker are provided for treatment of vasoconstrictive disorders. The endothelin antagonist is a pyrimidine- or triazine-substituted carboxylic acid [I; R = CHO, CN, CO₂H, tetrazolyl, etc.; R², R³ = H, OH, amino, halo, C₁₋₄ alkyl, haloalkyl, alkoxy, etc.; R⁴, R⁵ = (substituted) Ph or naphthyl, C₃₋₇ cycloalkyl; R⁶ = H, (substituted) alkyl, alkenyl, alkynyl, or cycloalkyl; X = N, CR¹⁴; R¹⁴ = H, C₁₋₅ alkyl; or R¹⁴CCR³ = 5- or 6-membered ring; Y = O, S, single bond; Z = O, S, SO, SO₂, single bond] or related compound. Thus, hard gelatin capsules were filled with I (R = CO₂H, R² = R³ = OMe, R⁴ = R⁵ = Ph, R⁶ = Me, X = CH, Y = Z = O) 100.0, bucindolol 30.0, lactose 18.0, PVP 15.0, microcryst. cellulose 17.5, Na carboxymethylstarch 10.0, talc 9.0, and Mg stearate 3.0 mg.


MSTR 1

G27-G3

G1 = tetrazolyl
G3 = 64


6G24-G25

G13 = Ph (opt. substd. by 1 or more G14)
G14 = halo
G17 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G18)
G18 = halo / Ph (opt. substd.)
G23 = O
G24 = O
G27 = 4



Patent location: claim 1
Note: additional ring formation also claimed

MSTR 5




G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G17 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G18)
 G18 = halo / Ph (opt. substd.)
 G23 = O
 Patent location: claim 1
 Note: additional ring formation also claimed

L89 ANSWER 19 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 130:257366 MARPAT [Full-text](#)
 TITLE: Multicomponent pharmaceutical formulations for
 treatment of cardiovascular disorders
 INVENTOR(S): Muentner, Klaus; Kirchengast, Michael; Hergenroeder,
 Stefan
 PATENT ASSIGNEE(S): Knoll A.-G. Chemische Fabriken, Germany
 SOURCE: Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19743142	A1	19990401	DE 1997-19743142	19970930
WO 9916446	A1	19990408	WO 1998-EP5916	19980917
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE AU 9897447 A 19990423 AU 1998-97447 19980917 PRIORITY APPLN. INFO.: DE 1997-19743142 19970930 WO 1998-EP5916 19980917				

GI



AB Novel combinations of an endothelin antagonist and a calcium antagonist are provided for treatment of cardiovascular disorders. The endothelin antagonist is a pyrimidine- or triazine-substituted carboxylic acid [I; R = CHO, CN, CO₂H, tetrazolyl, etc.; R₂, R₃ = H, OH, amino, halo, C₁-4 alkyl, haloalkyl, alkoxy, etc.; R₄, R₅ = (substituted) Ph or naphthyl, C₃-7 cycloalkyl; R₆ = H, (substituted) alkyl, alkenyl, alkynyl, or cycloalkyl; X = N, CR₁₄; R₁₄ = H, C₁-5 alkyl; or R₁₄CCR₃ = 5- or 6-membered ring; Y = O, S, single bond; Z = O, S, SO, SO₂, single bond] or related compound. Thus, hard gelatin capsules were filled with I (R = CO₂H, R₂ = R₃ = OMe, R₄ = R₅ = Ph, R₆ = Me, X = CH, Y = Z = O) 100.0, gallopamil 75.0, lactose 18.0, PVP 15.0, microcryst. cellulose 17.5, Na carboxymethylstarch 10.0, talc 9.0, and Mg stearate 3.0 mg.


MSTP 1

G27—G3

G1 = tetrazolyl
G3 = 64


⁶G24—G25

G13 = Ph (opt. substd. by 1 or more G14)
G14 = halo
G17 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G18)
G18 = halo / Ph (opt. substd.)
G23 = O
G24 = O
G27 = 4



Patent location: claim 1
Note: additional ring formation also claimed


MSTR 5



G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G17 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G18)
 G18 = halo / Ph (opt. substd.)
 G23 = O
 Patent location: claim 1
 Note: additional ring formation also claimed

L89 ANSWER 20 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 130:257365 MARPAT Full-text
 TITLE: Multicomponent pharmaceutical formulations for treatment of kidney failure
 INVENTOR(S): Hahn, Alfred; Kirchengast, Michael; Muentner, Klaus
 PATENT ASSIGNEE(S): Knoll A.-G. Chemische Fabriken, Germany
 SOURCE: Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19743141	A1	19990401	DE 1997-19743141	19970930
CA 2304712	A1	19990408	CA 1998-2304712	19980910
WO 9916445	A1	19990408	WO 1998-EP5773	19980910
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9895395	A	19990423	AU 1998-95395	19980910
AU 750755	B2	20020725		
EP 1014989	A1	20000705	EP 1998-948954	19980910
EP 1014989	B1	20040114		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE, FI				
JP 2001517704	T	20011009	JP 2000-513581	19980910
HU 2000004298	A2	20011128	HU 2000-4298	19980910
AT 257706	T	20040115	AT 1998-948954	19980910
ES 2214734	T3	20040916	ES 1998-948954	19980910
US 6329384	B1	20011211	US 2000-508993	20000320
NO 2000001548	A	20000324	NO 2000-1548	20000324
NO 324382	B1	20071001		
PRIORITY APPLN. INFO.:			DE 1997-19742717	19970926
			DE 1997-19743141	19970930
			WO 1998-EP5773	19980910



AB Novel combinations of an endothelin antagonist and an ACE inhibitor are provided for treatment of kidney failure. The endothelin antagonist is a pyrimidine- or triazine-substituted carboxylic acid [I; R = CHO, CN, CO₂H, tetrazolyl, etc.; R₂, R₃ = H, OH, amino, halo, C1-4 alkyl, haloalkyl, alkoxy, etc.; R₄, R₅ = (substituted) Ph or naphthyl, C3-7 cycloalkyl; R₆ = H, (substituted) alkyl, alkenyl, alkynyl, or cycloalkyl; X = N, CR₁₄; R₁₄ = H, C1-5 alkyl; or R₁₄CCR₃ = 5- or 6-membered ring; Y = O, S, single bond; Z = O, S, SO, SO₂, single bond] or related compound. Thus, hard gelatin capsules were filled with I (R = CO₂H, R₂ = R₃ = OMe, R₄ = R₅ = Ph, R₆ = Me, X = CH, Y = Z = O) 100.0, ramipril 2.5, lactose 18.0, PVP 15.0, microcryst. cellulose 17.5, Na carboxymethylstarch 10.0, talc 9.0, and Mg stearate 3.0 mg.


MSR 1

G27-G3

G1 = tetrazolyl
G3 = 64

G24-G25

G13 = Ph (opt. substd. by 1 or more G14)
G14 = halo
G17 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G18)
G18 = halo / Ph (opt. substd.)
G23 = O
G24 = O
G27 = 4




Patent location: claim 1

10/566911

Note: additional ring formation also claimed

MSTR 5



G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G17 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G18)
 G18 = halo / Ph (opt. substd.)
 G23 = O

Patent location:

claim 1

Note:

additional ring formation also claimed

L89 ANSWER 21 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 130:257364 MARPAT Full-text

TITLE: Multicomponent pharmaceutical formulations for treatment of cardiovascular disorders

INVENTOR(S): Muentner, Klaus; Kirchengast, Michael; Klein, Gisela; Koriath, Horst

PATENT ASSIGNEE(S): Knoll A.-G. Chemische Fabriken, Germany

SOURCE: Ger. Offen., 34 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19743140	A1	19990401	DE 1997-19743140	19970930

PRIORITY APPLN. INFO.: DE 1997-19743140 19970930

GI



AB Novel combinations of an endothelin antagonist and a vasodilator are provided for treatment of cardiovascular disorders. The endothelin antagonist is a pyrimidine- or triazine-substituted carboxylic acid [I; R = CHO, CN, CO₂H,

tetrazolyl, etc.; R2, R3 = H, OH, amino, halo, C1-4 alkyl, haloalkyl, alkoxy, etc.; R4, R5 = (substituted) Ph or naphthyl, C3-7 cycloalkyl; R6 = H, (substituted) alkyl, alkenyl, alkynyl, or cycloalkyl; X = N, CR14; R14 = H, C1-5 alkyl; or R14CCR3 = 5- or 6-membered ring; Y = O, S, single bond; Z = O, S, SO, SO2, single bond) or related compound. Thus, administration of a combination of I (R = CO2H, R2 = R3 = OMe, R4 = R5 = Ph, R6 = Me, X = CH, Y = Z = O) (II) and hydralazine (5 and 0.5 mg/kg, resp.) orally to normal male beagles synergistically decreased their mean arterial pressure after 2 h by 15.4 mm Hg. Hard gelatin capsules were prepared containing II 200.0, hydralazine 50.0, lactose 18.0, PVP 15.0, microcryst. cellulose 17.5, Na carboxymethylstarch 10.0, talc 9.0, and Mg stearate 3.0 mg.


MSTR 1

G27-G3

G1 = tetrazolyl
G3 = 64

G24-G25

G13 = Ph (opt. substd. by 1 or more G14)
G14 = halo
G17 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G18)
G18 = halo / Ph (opt. substd.)
G23 = O
G24 = O
G27 = 4




Patent location:

claim 1

Note:

additional ring formation also claimed

MSTR 5




G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G17 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G18)
 G18 = halo / Ph (opt. substd.)
 G23 = O
 Patent location: claim 1
 Note: additional ring formation also claimed

L89 ANSWER 22 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 130:257363 MARPAT Full-text
 TITLE: Multicomponent pharmaceutical formulations for
 treatment of cardiovascular disorders
 INVENTOR(S): Muentner, Klaus; Kirchengast, Michael; Koriath, Horst
 PATENT ASSIGNEE(S): Knoll A.-G. Chemische Fabriken, Germany
 SOURCE: Ger. Offen., 36 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19742717	A1	19990401	DE 1997-19742717	19970926
CA 2304712	A1	19990408	CA 1998-2304712	19980910
WO 9916445	A1	19990408	WO 1998-EP5773	19980910
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, KG, MD, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9895395	A	19990423	AU 1998-95395	19980910
AU 750755	B2	20020725		
EP 1014989	A1	20000705	EP 1998-948954	19980910
EP 1014989	B1	20040114		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE, FI				
JP 2001517704	T	20011009	JP 2000-513581	19980910
HU 2000004298	A2	20011128	HU 2000-4298	19980910
AT 257706	T	20040115	AT 1998-948954	19980910
RU 2222328	C2	20040127	RU 2000-110630	19980910
ES 2214734	T3	20040916	ES 1998-948954	19980910
MX 200002655	A	20001211	MX 2000-2655	20000316
US 6329384	B1	20011211	US 2000-508993	20000320
NO 2000001548	A	20000324	NO 2000-1548	20000324
NO 324382	B1	20071001		
PRIORITY APPLN. INFO.:			DE 1997-19742717	19970926
			DE 1997-19743141	19970930
			WO 1998-EP5773	19980910

GI



AB Novel combinations of an endothelin antagonist and an inhibitor of the renin-angiotensin system are provided for treatment of cardiovascular disorders. The endothelin antagonist is a pyrimidine- or triazine-substituted carboxylic acid [I; R = CHO, CN, CO₂H, tetrazolyl, etc.; R², R³ = H, OH, amino, halo, C1-4 alkyl, haloalkyl, alkoxy, etc.; R⁴, R⁵ = (substituted) Ph or naphthyl, C3-7 cycloalkyl; R⁶ = H, (substituted) alkyl, alkenyl, alkynyl, or cycloalkyl; X = N, CR¹⁴; R¹⁴ = H, C1-5 alkyl; or R¹⁴CCR³ = 5- or 6-membered ring; Y = O, S, single bond; Z = O, S, SO, SO₂, single bond] or related compound. Thus, administration of a combination of I (R = CO₂H, R² = R³ = OMe, R⁴ = R⁵ = Ph, R⁶ = Me, X = CH, Y = Z = O) (II) andtrandolapril (2 and 10 mg/kg, resp.) orally to normal male beagles decreased their mean arterial pressure after 2 h by 30.9 mm Hg and increased the heart rate by 25.4/min. Hard gelatin capsules were prepared containing II 250.0, ramipril 2.5, lactose 18.0, PVP 15.0, microcryst. cellulose 17.5, Na carboxymethylstarch 10.0, talc 9.0, and Mg stearate 3.0 mg.


MSSTP 1

G27—G3

G1 = tetrazolyl
G3 = 64


G24—G25

G13 = Ph (opt. substd. by 1 or more G14)
G14 = halo
G17 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G18)
G18 = halo / Ph (opt. substd.)
G23 = O
G24 = O
G27 = 4



Patent location: claim 1
 Note: additional ring formation also claimed

NSTEP 5



G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G17 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G18)
 G18 = halo / Ph (opt. substd.)
 G23 = O

Patent location: claim 1
 Note: additional ring formation also claimed


L89 ANSWER 23 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 129:275935 MARPAT Full-text
 TITLE: Novel pyrimidine- and triazine-containing carboxylic acid derivatives, their preparation, and use as endothelin receptor antagonists in treating cancer
 INVENTOR(S): Romerdahl, Cynthia A.
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841206	A1	19980924	WO 1998-US4596	19980309
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6030975	A	20000229	US 1997-818622	19970314
CA 2283732	A1	19980924	CA 1998-2283732	19980309
AU 9866946	A	19981012	AU 1998-66946	19980309
AU 744019	B2	20020214		
EP 969841	A1	20000112	EP 1998-909067	19980309
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
BR 9808263	A	20000516	BR 1998-8263	19980309

10/566911


HU 2000002249	A2	20010528	HU 2000-2249	19980309
HU 2000002249	A3	20011128		
JP 2001517220	T	20011002	JP 1998-540573	19980309
IN 1998MA00509	A	20050304	IN 1998-MA509	19980312
ZA 9802136	A	19990913	ZA 1998-2136	19980313
NO 9904426	A	19991112	NO 1999-4426	19990913
PRIORITY APPLN. INFO.:			US 1997-818622	19970314
			WO 1998-US4596	19980309

GI



AB The invention provides a method for treating cancer, wherein the cancer is a tumor in which endothelin (ET) is upregulated (e.g. tumors of the prostate, lung, liver, breast, brain, stomach, colon, endometrium, testicle, thyroid, pituitary, bladder, kidney, pancreas and meninges), by administering a compound I [R = CHO, tetrazolyl, cyano, CO₂H or its hydrolyzable derivs.; R₂ = H, OH, (di)(alkyl)amino, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio; X = N, CH, C-alkyl, or forms a 5- or 6-ring to R₃; R₃ = groups given for R₂, or NHO-alkyl, or forms 5- or 6-ring to X; R₄, R₅ = (un)substituted Ph, naphthyl, or certain fused derivs.; or R₄ = a wide variety of possible substituents and R₅ = H, alk(en/yn)yl, cycloalkyl, haloalkyl, Ph, etc.; or R₄R₅ forms (un)substituted 3- to 8-ring; R₆ = H, (un)substituted alk(en/yn)yl, cycloalkyl, Ph, naphthyl, heteroaryl; Y, Z = S, O, bond; with provisos]. Over 150 compds. were prepared. For instance, methanolysis of Me 3,3-diphenyl-2,3-epoxypropionate in the presence of BF₃·OEt₂ gave 88% Me 2-hydroxy-3-methoxy-3,3-diphenylpropionate, which was etherified with 4,6-dimethoxy-2-(methylsulfonyl)pyrimidine to give 82% title compound II. At 150 mg/kg/day i.p. in mice in the DU-145 prostate tumor model, II reduced mean tumor weight to 33% of control after 10 days.

MSTR 1B



G₁ = tetrazolyl
 G₈ = Ph (opt. substd. by 1 or more G₉)
 G₉ = halo
 G₁₅ = 235

235-23

G16 = halo / Ph (opt. substd.)
 G22 = O
 G23 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G16)
 G24 = O

Patent location: claim 1

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L89 ANSWER 24 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 127:358879 MARPAT Full-text
 TITLE: Preparation of 1-(3-heterocyclylphenyl)-s-triazine-
 2,4,6-oxo- or -thiotrione herbicidal agents
 INVENTOR(S): Crews, Alvin Donald, Jr.; Karp, Gary Mitchell;
 Manfredi, Mark Christopher; Guaciario, Michael Anthony
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: U.S., 49 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5679791	A	19971021	US 1996-686288	19960725
PRIORITY APPLN. INFO.:			US 1996-686288	19960725
OTHER SOURCE(S):		CASREACT 127:358879		
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R = H, C1-6 alkyl, C2-12 alkoxyalkyl, etc.; R1 = H, C3-6 alkenyl, C3-6 alkynyl, etc.; R11, R12 = H, (un)substituted C1-6 alkyl, C3-6 cycloalkyl; R11R12 = (un)substituted 4-7 membered (un)saturated ring optionally interrupted by O, S(O)r, or N; A, A1, A2 = O, S; r = 0-2; X, Y = H, halo, NO2, CN], useful for the control of undesirable plant species, were prepared by reacting an isothiocyanate II with a hydrazine R12NHNHR11 followed by reaction of the resulting intermediate III with phosgene or a phosgene equivalent in the presence of a base. Thus, the title compound IV showed 100% efficacy against, e.g., common lambsquarters in preemergence test at 0.125 kg/ha.

MGSR 1



G6 = alkyl <containing 1-12 C>
 (opt. substd. by 1 or more G7)
 G7 = CN / 26 / 34 / OH / 45 / 48 /
 Ph (opt. substd. by (1-3) G21)




G8 = 38



G9 = O
 G10 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G13)
 G13 = F / Ph (opt. substd. by 1 or more G12)
 G21 = F

Patent location: claim 1
 Note: substitution is restricted

MSTR 2



G6 = alkyl <containing 1-12 C>
 (opt. substd. by 1 or more G7)
 G7 = CN / 26 / 34 / OH / 45 / 48 /
 Ph (opt. substd. by (1-3) G21)

10/566911



G8 = 38



G9 = O

G10 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G13)


G13 = F / Ph (opt. substd. by 1 or more G12)

G21 = F

Patent location: claim 1

Note: substitution is restricted


MSTR 4



G6 = alkyl <containing 1-12 C>

(opt. substd. by 1 or more G7)

G7 = CN / 26 / 99 / 34 / OH / 45 / 48 /
Ph (opt. substd. by (1-3) G21)




G8 = 38

G9 = O
 G10 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G13)
 G13 = F / Ph (opt. substd. by 1 or more G12)
 G21 = F
 Patent location: disclosure
 Note: substitution is restricted
 Note: additional ring formation also disclosed


L89 ANSWER 25 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 127:346409 MARPAT Full-text
 TITLE: Preparation of pyrimidinylxypropionates and related
 compounds as endothelin antagonists.
 INVENTOR(S): Amberg, Wilhelm; Kling, Andreas; Klinge, Dagmar;
 Riechers, Hartmut; Baumann, Ernst; Unger, Liliane;
 Raschack, Manfred; Hergenroeder, Stefan; Schult,
 Sabine
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 25 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19614542	A1	19971016	DE 1996-19614542	19960412
CA 2250764	A1	19971023	CA 1997-2250764	19970404
WO 9738982	A1	19971023	WO 1997-EP1687	19970404
W: AU, BG, BR, CA, CN, CZ, GE, HU, IL, JP, KR, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9726364	A	19971107	AU 1997-26364	19970404
AU 711293	B2	19991007		
EP 892788	A1	19990127	EP 1997-918109	19970404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
CN 1216042	A	19990505	CN 1997-193737	19970404
BR 9708614	A	19990803	BR 1997-8614	19970404
NZ 331704	A	20000623	NZ 1997-331704	19970404
JP 2000508325	T	20000704	JP 1997-536698	19970404
TR 9802042	T2	20000921	TR 1998-2042	19970404
IN 1997MA00755	A	20050304	IN 1997-MA755	19970410
ZA 9703096	A	19981012	ZA 1997-3096	19970411
TW 419465	B	20010121	TW 1997-86104674	19970411
BG 63202	B1	20010629	BG 1998-102770	19980915
US 6103732	A	20000815	US 1998-155948	19981008
NO 9804713	A	19981009	NO 1998-4713	19981009
NO 311802	B1	20020128		
KR 2000005366	A	20000125	KR 1998-708088	19981010
PRIORITY APPLN. INFO.:			DE 1996-19614542	19960412
			WO 1997-EP1687	19970404
OTHER SOURCE(S):		CASREACT 127:346409		



AB Title compds. [I; R = tetrazolyl, cyano, acyl; R2 = H, OH, amino, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, etc.; R3 = H, OH, amino, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyamino, alkylthio, etc.; R4, R5 = (substituted) Ph, naphthyl; R6 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, naphthyl, heteroaryl; X = N, CR12; R12 = H, alkyl; R2R12 or R3R12 = alkylene, alkenylene; Y = N, CH, Z = O, S], were prepared Thus, Me 2-hydroxy-3-methoxy-3,3-diphenylpropionate (preparation given), 2,6-dimethoxy-4-chloropyrimidine, and K2CO3 were stirred at 100° in DMF to give Me 2-(2,6-dimethoxypyrimidin-4-yloxy)-3-methoxy- 3,3-diphenylpropionate. I bound to ETA receptors with Ki = 0.038-3.3 μM.

MSTR 1



G1 = tetrazolyl
 G40 = Ph (opt. substd. by 1 or more G41)
 G41 = halo
 G44 = O
 G45 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G46)
 G46 = halo / Ph (opt. substd. by 1 or more G51)
 Patent location: claim 1
 Note: additional ring formation also claimed

L89 ANSWER 26 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 127:346399 MARPAT [Full-text](#)
 TITLE: Preparation of 1-(3-substituted-1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0^{2,6}]heptanes for treating CNS disorders

INVENTOR(S): Jeppesen, Lone; Olesen, Preben H.; Sauerberg, Per
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

10/566911

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736906	A1	19971009	WO 1997-DK142	19970402
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5914338	A	19990622	US 1997-831358	19970401
IN 1997MA00679	A	20050304	IN 1997-MA679	19970401
ZA 9702790	A	19971002	ZA 1997-2790	19970402
CA 2250843	A1	19971009	CA 1997-2250843	19970402
AU 9722871	A	19971022	AU 1997-22871	19970402
EP 891363	A1	19990120	EP 1997-915354	19970402
EP 891363	B1	20030827		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 11509864	T	19990831	JP 1997-534844	19970402
JP 3162727	B2	20010508		
AT 248172	T	20030915	AT 1997-915354	19970402
PRIORITY APPLN. INFO.:			DK 1996-377	19960402
			DK 1996-1281	19961114
			WO 1997-DK142	19970402

GI



I

AB The title compds. [I; R = H, halo, C3-8 cycloalkyl, etc.] and their salts, useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system, were prepared and formulated. Thus, reduction of 1-cyano-4-azatricyclo[2.2.1.0^{2,6}]heptane with DIBAL-H in THF followed by treatment of the resulting 1-formyl-4-azatricyclo[2.2.1.0^{2,6}]heptane with KCN in H₂O, reaction of the resulting cyanohydrin with NH₄Cl in ammonia aqueous solution, cyclization of 2-amino-2-(4-azatricyclo[2.2.1.0^{2,6}]hept-1-yl)acetonitrile with sulfur monochloride in DMF, and reaction of 1-(3-chloro-1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0^{2,6}]heptane with 1-Pr bromide afforded I.oxalate [R = Pr] which showed IC₅₀ of 4.3 nM against specific binding of 3H-Oxo.

MSTR 1



G1 = 16 / 18 / 24 / 28 / 33

1⁶5—G6 1⁶7—G8 2⁶7—G11—G7—G13 2⁶7—G11—G14

3⁶7—G15—G16

G2 = F / Ph (opt. substd. by 1 or more G9)

G6 = carbon chain <containing 1-15 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by 1 or more G2)

G7 = O

G9 = F

G11 = carbon chain <containing 1-15 C,
0 or more double bonds, 0 or more triple bonds>
(opt. substd. by 1 or more G12)

G12 = CF₃ / CN / Ph (opt. substd. by 1 or more G9)

G14 = 31

3⁶7—G6

Patent location: claim 1

L89 ANSWER 27 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 125:58749 MARPAT [Full-text](#)

TITLE: High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof

INVENTOR(S): Grubbs, Robert H.; Nguyen, Sonbinh T.; Johnson, Lynda K.; Hillmyer, Marc A.; Fu, Gregory C.

PATENT ASSIGNEE(S): California Institute of Technology, USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9604289	A1	19960215	WO 1995-US9655	19950728
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2196061	A1	19960215	CA 1995-2196061	19950728
CA 2196061	C	20000613		
AU 9532728	A	19960304	AU 1995-32728	19950728
AU 691645	B2	19980521		
EP 773948	A1	19970521	EP 1995-929340	19950728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09512828	T	19971222	JP 1995-506676	19950728
JP 3067031	B2	20000717		
JP 3067031	B2	20000717	JP 1996-506676	19950728
EP 1251135	A2	20021023	EP 2002-16470	19950728
EP 1251135	A3	20040102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1253156	A2	20021030	EP 2002-16469	19950728
EP 1253156	A3	20040107		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 5880231	A	19990309	US 1995-548445	19951026
US 5922863	A	19990713	US 1995-548915	19951026
US 5728917	A	19980317	US 1995-550300	19951030
US 5750815	A	19980512	US 1996-705064	19960829
US 5710298	A	19980120	US 1996-708057	19960830
US 5969170	A	19991019	US 1997-862615	19970523
US 5849851	A	19981215	US 1997-969969	19971113
JP 11261667	A	19990928	JP 1998-256943	19980910
JP 3352035	B2	20021203		
PRIORITY APPLN. INFO.:			US 1994-282826	19940729
			US 1994-282827	19940729
			US 1992-863606	19920403
			US 1993-106292	19930813
			EP 1995-929340	19950728
			JP 1995-506676	19950728
			WO 1995-US9655	19950728
			US 1995-548446	19951026
			US 1995-550679	19951031
OTHER SOURCE(S):	CASREACT 125:58749			
GI				



AB Ru and Os carbene compds. which are stable in the presence of a variety of functional groups and which can be used to catalyze olefin metathesis reactions are discussed. Methods for synthesizing these carbene compds. are also disclosed. For example, 1.73 mmol [(cymene)RuCl₂]₂, 2 equiv PCy₃ and 1

equiv 3,3-diphenylcyclopropene react in benzene at 83-85° for 6 h to give 88% C12Ru(:CHCH:CPH2)(PCy3)2 (I). Phosphoranes, R4R5R6P:CRR1, can be used in place of cyclopropenes. Specifically, the present invention relates to carbene compds. I wherein: M is Os or Ru; R and R1 are independently selected from H; C2-C20 alkenyl, C2-C20 alkynyl, C1-C20 alkyl, aryl, C1-C20 carboxylate, C2-C20 alkoxy, C2-C20 alkenyloxy, C2-C20 alkynyloxy, aryloxy, C2-C20 alkoxycarbonyl, C1-C20 alkylthio, C1-C20 alkylsulfonyl or C1-C20 alkylsulfinyl; each optionally substituted with C1-C5 alkyl, halogen, C1-C5 alkoxy or with a Ph group optionally substituted with halogen, C1-C5 alkyl or C1-C5 alkoxy; X and X1 are independently selected from any anionic ligand; and L and L1 are each trialkylphosphine ligands where at least one of the alkyl groups on the phosphine is a secondary alkyl or a cycloalkyl. In a preferred embodiment, all of the alkyl groups of the trialkylphosphine are either a secondary alkyl or a cycloalkyl. In a more preferred embodiment, the alkyl groups are either iso-Pr, iso-Bu, sec-Bu, neopentyl, neophenyl, cyclopentyl or cyclohexyl. Reactions catalyzed by the above complexes include ring-opening metathesis polymerization of strained and unstrained cyclic olefins, ring closing metathesis of acyclic dienes, cross metathesis reactions involving at least one acyclic or unstrained cyclic olefin and depolymn. of olefinic polymers. For example, 0.50 mmol CH2:CHCH2OCHPhCH2CH:CH2 was converted in 86% yield to the dihydropyran in benzene in the presence of I after 5 h at 20°. Telechelic polymers can be prepared using the above complexes as catalysts.

MSTR 1



- G2 = alkenyloxy <containing 2-20 C>
(opt. substd. by 1 or more G24)
G23 = 204



- G24 = F / Ph (opt. substd. by 1 or more G25)
G25 = F
G26 = alkoxy <containing 1-5 C> /
Ph (opt. substd. by 1 or more G25)
G27 = carbon chain (opt. substd. by 1 or more G26)
Patent location: claim 1
Note: additional ring formation specified

L89 ANSWER 28 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 125:58534 MARPAT Full-text
TITLE: Preparation of pyrimidine- and triazine-derivative

endothelin receptor antagonists
 INVENTOR(S): Riechers, Hartmut; Klinge, Dagmar; Amberg, Wilhelm;
 Kling, Andreas; Mueller, Stefan; Baumann, Ernst;
 Rheinheimer, Joachim; Vogelbacher, Uwe Josef; Wernet,
 Wolfgang; et al.
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 28 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19533023	A1	19960418	DE 1995-19533023	19950907
DE 19533023	B4	20070516		
CA 2201785	A1	19960425	CA 1995-2201785	19951007
CA 2201785	C	20060829		
WO 9611914	A1	19960425	WO 1995-EP3963	19951007
W: AU, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9538045	A	19960506	AU 1995-38045	19951007
AU 688611	B2	19980312		
EP 785926	A1	19970730	EP 1995-935916	19951007
EP 785926	B1	20010822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1160396	A	19970924	CN 1995-195655	19951007
BR 9509338	A	19971104	BR 1995-9338	19951007
HU 77443	A2	19980428	HU 1997-1975	19951007
HU 220621	B1	20020328		
JP 10507190	T	19980714	JP 1996-512911	19951007
JP 3957748	B2	20070815		
EP 1110952	A1	20010627	EP 2001-103889	19951007
EP 1110952	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 204568	T	20010915	AT 1995-935916	19951007
ES 2162942	T3	20020116	ES 1995-935916	19951007
PT 785926	T	20020228	PT 1995-935916	19951007
RU 2180335	C2	20020310	RU 1997-107617	19951007
PL 186850	B1	20040331	PL 1995-319655	19951007
CN 1513844	A	20040721	CN 2004-10002783	19951007
AT 277911	T	20041015	AT 2001-103889	19951007
CZ 294603	B6	20050216	CZ 1997-1132	19951007
ES 2226996	T3	20050401	ES 2001-103889	19951007
CN 1923820	A	20070307	CN 2006-10099954	19951007
IL 115560	A	20030212	IL 1995-115560	19951011
ZA 9508642	A	19970414	ZA 1995-8642	19951013
HR 950517	B1	20040630	HR 1995-517	19951013
TW 577880	B	20040301	TW 1995-84110900	19951017
US 5932730	A	19990803	US 1997-809699	19970327
FI 9701529	A	19970411	FI 1997-1529	19970411
NO 9701675	A	19970610	NO 1997-1675	19970411
NO 308846	B1	20001106		
US 5969134	A	19991019	US 1998-184152	19981102
US 6197958	B1	20010306	US 1999-309770	19990511
US 20020052495	A1	20020502	US 2000-748184	20001227
US 6600043	B2	20030729		
GR 3036931	T3	20020131	GR 2001-401798	20011018



US 7109205	B2	20060919	US 2003-602275	20030624
US 20040092742	A1	20040513		
HR 2004000364	B1	20060930	HR 2004-364	20040422
HK 1066541	A1	20070601	HK 2004-109463	20041201
US 20060160808	A1	20060720	US 2006-377879	20060316
US 7119097	B2	20061010		
US 20060276645	A1	20061207	US 2006-502257	20060810
US 20060276474	A1	20061207	US 2006-502293	20060810
JP 2007126488	A	20070524	JP 2007-40759	20070221
JP 2007137892	A	20070607	JP 2007-40760	20070221
JP 2007137893	A	20070607	JP 2007-40761	20070221
JP 2007169295	A	20070705	JP 2007-40758	20070221
US 20070203338	A1	20070830	US 2007-789630	20070425

PRIORITY APPLN. INFO.:

DE 1994-4436851 19941014
 DE 1995-19533023 19950907
 CN 2004-10002783 19951007
 EP 1995-935916 19951007
 JP 1996-512911 19951007
 WO 1995-EP3963 19951007
 US 1997-809699 19970327
 US 1998-184152 19981102
 US 1999-309770 19990511
 US 2000-748184 20001227
 US 2003-602275 20030624
 US 2006-502257 20060810


OTHER SOURCE(S): CASREACT 125:58534

GI



AB The title compds. [I; R = CHO, tetrazolyl, CN, CO₂H, groups cleavable to CO₂H; R₂ = (un)substituted NH₂, halogen, (un)substituted alkyl, etc.; R₃ = H, OH, (un)substituted NH₂, halogen, (un)substituted alkyl, etc.; R₄, R₅ = (un)substituted Ph or naphthyl; R₆ = H, alkyl, alkenyl, alkynyl, alkylcarbonyl, (un)substituted Ph, etc.; X = N, (un)substituted CH; Y = direct bond, S, O; Z = S, O, SO, SO₂, direct bond], useful as endothelin receptor antagonists, are prepared. Thus, pyrimidine derivative II, m.p. 167°, demonstrated a K_i ETA of 6 nM.

MSTR 1A



G1 = tetrazolyl
 G13 = Ph (opt. substd. by 1 or more G14)
 G14 = halo
 G26 = alkenyl <containing 3-6 C>
 (opt. substd. by 1 or more G27)
 G27 = halo / Ph (opt. substd. by 1 or more G28)
 G33 = O
 G34 = O
 Patent location: claim 1
 Note: substitution is restricted

L89 ANSWER 29 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 123:307319 MARPAT Full-text
 TITLE: Carboxylic acid derivatives as inhibitors of
 endothelin binding to receptors
 INVENTOR(S): Baumann, Ernst; Vogelbacher, Uwe Josef; Rheinheimer,
 Joachim; Klinge, Dagmar; Riechers, Hartmut; Kroeger,
 Burkhard; Bialojan, Siegfried; Bollschweiler, Claus;
 Wernet, Wolfgang; et al.
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 31 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4411225	A1	19951005	DE 1994-4411225	19940331
HR 950115	B1	20011231	HR 1995-115	19950309
CA 2186784	A1	19951012	CA 1995-2186784	19950323
CA 2186784	C	20070220		
WO 9526716	A1	19951012	WO 1995-EP1099	19950323
W: AU, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9521356	A	19951023	AU 1995-21356	19950323
AU 695193	B2	19980806		
EP 752854	A1	19970115	EP 1995-914301	19950323
EP 752854	B1	20010822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1148807	A	19970430	CN 1995-193167	19950323
CN 1070701	B	20010912		
HU 75305	A2	19970528	HU 1996-2695	19950323
BR 9507231	A	19970916	BR 1995-7231	19950323
JP 09510984	T	19971104	JP 1995-525391	19950323
JP 4001622	B2	20071031		
PL 179580	B1	20000929	PL 1995-316563	19950323
RU 2163808	C2	20010310	RU 1996-121628	19950323
AT 204471	T	20010915	AT 1995-914301	19950323
ES 2162916	T3	20020116	ES 1995-914301	19950323
PT 752854	T	20020228	PT 1995-914301	19950323
CZ 290684	B6	20020911	CZ 1996-2873	19950323
IL 113137	A	19991028	IL 1995-113137	19950327
TW 382594	B	20000221	TW 1995-84103012	19950328
ZA 9502614	A	19960930	ZA 1995-2614	19950330
FI 9603885	A	19961126	FI 1996-3885	19960927


10/566911

FI 118589	B1	20080115
NO 9604121	A	19961126
NO 310497	B1	20010716
US 5840722	A	19981124
GR 3036606	T3	20011231
JP 2007131645	A	20070531

PRIORITY APPLN. INFO.:


NO 1996-4121	19960927
US 1996-718377	19960930
GR 2001-401467	20010912
JP 2007-34659	20070215
DE 1994-4411225	19940331
JP 1995-525391	19950323
WO 1995-EP1099	19950323

GI



AB Carboxylic acid derivs. I [R = CHO, CO₂H, group hydrolyzable to CO₂H; R₂, R₃ = halo, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkylthio; X = N, CR₁₄; R₄ = (substituted) C1-10 alkyl, (substituted) C3-12 cycloalkyl or cycloalkenyl, (substituted) C3-6 alkenyl or alkynyl, (substituted) heterocyclyl, (substituted) Ph or naphthyl; R₅ = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, or R₄ and R₅ complete a 3-8-membered ring; R₆ = (substituted) alkyl, (substituted) alkenyl, (substituted) alkynyl, (substituted) cycloalkyl; R₁₄ = H or forms an O-containing 3-4-membered alkylene or alkenylene chain with R₃; Y = S, O, single bond; Z = S, O] are prepared as inhibitors of endothelin binding to receptors for treatment of e.g. (pulmonary) hypertension, acute myocardial infarct, Raynaud's syndrome, atherosclerosis, and asthma. Thus, I (R₁ = CO₂H, R₂ = R₃ = OMe, R₄ = Ph, R₅ = Me, R₆ = 4-isopropylphenyl, X = CH, Y = Z = O) inhibited binding of endothelin to endothelin A receptors of cloned human CHO cells and endothelin B receptors of guinea pig cerebellar membranes with K_i 2.5 × 10⁻⁷ and 3.0 × 10⁻⁶M, resp. I (R = CO₂Me, R₂ = R₃ = OMe, R₄ = R₆ = Ph, R₅ = H, X = CH, Y = S, Z = O) was prepared by reaction of Me 3-phenoxy-3-phenyl-2-hydroxybutyrate (preparation given) with MeSO₂Cl and 4,6-dimethoxyprimidine-2-thiol.

MSTR 1



G3 = 6



G4 = N
G9 = 36





G10 = Ph (opt. substd. by 1 or more G16)
G16 = halo
G18 = alkyl <containing 1-3 C>
(substd. by alkoxy <containing 1-3 C>)
G26 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G27)
G27 = halo / Ph (opt. substd.)
G43 = O
Patent location: claim 1
Note: substitution is restricted

L89 ANSWER 30 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 122:161364 MARPAT Full-text
TITLE: Preparation of N-acyl β -amino acid derivatives as
platelet aggregation inhibitors
INVENTOR(S): Tjoeng, Foe S.; Toth, Mihaly V.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Monsanto Co.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9420457	A1	19940915	WO 1994-US1594	19940222
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9462678	A	19940926	AU 1994-62678	19940222
US 5710166	A	19980120	US 1995-518660	19950824
PRIORITY APPLN. INFO.:			US 1993-24977	19930302
			WO 1994-US1594	19940222

GI



AB Title compds. I (R = H, alkyl, alkenyl, alkynyl, acyclyl, and aromatic all optionally substituted, (substituted)heterocyclyl; A = alkyl, alkenyl, alkynyl, alicyclyl, heterocyclyl, aryl all optionally substituted; W = H, alkyl, alkenyl, alkynyl, alicyclyl, aromatic all optionally substituted; Z, Z' = H, alkyl, halo, alkoxy, NC, SO₂, HO; m = 0-6; n = 0-3) or a pharmaceutically acceptable salt, are prepared 4-Cyanobenzaldehyde, 3-aminobenzoic acid and NaBH₃CN were reacted to give 3-(4- cyanobenzyl)aminobenzoic acid which was reacted with β-alanine Et ester-HCl, EtN(Me₂CH)₂ and (benzotriazol-1- yloxy)tris(dimethylamino)phosph onium hexafluorophosphate to give Et β-[[3-[4(aminoiminomethyl)benzyl]aminobenzoyl]aminol]propanoate which was treated with 1N LiOH and MeOH to give the title compound II. In vitro platelet aggregation inhibition in platelet-rich plasma in dog of II was IC₅₀ = 28% at 10-5M.

MSTP 1



- G1 = alkyl <containing 1-10 C>
(opt. substd. by 1 or more G2)
G2 = alkyl <containing 1-10 C> / F / CO₂H / CF₃ /
Ph (opt. substd. by 1 or more G3)
G3 = F
G8 = 13

G9—G9

- G9 = alkenyl <containing 2-10 C>
(opt. substd. by 1 or more G2)
G12 = 27

G15—G16



G13 = (0-6) CH2
 G16 = alkoxy <containing 1-10 C>
 Derivative: or pharmaceutically acceptable salts
 Patent location: claim 1

L89 ANSWER 31 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 122:31550 MARPAT Full-text
 TITLE: Preparation of 3-(hetero)arylcarboxylic acid-derivative herbicides with increased species selectivity
 INVENTOR(S): Baumann, Ernst; Rheinheimer, Joachim; Vogelbacher, Uwe; Josef; Bratz, Matthias; Theobald, Hans; Gerber, Matthias; Walter, Helmut; Rademacher, Wilhelm; Westphalen, Karl Otto
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 25 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4313412	A1	19941027	DE 1993-4313412	19930423
CA 2160912	A1	19941110	CA 1994-2160912	19940413
CA 2160912	C	20071002		
WO 9425442	A1	19941110	WO 1994-EP1141	19940413
W: AU, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9465681	A	19941121	AU 1994-65681	19940413
AU 678236	B2	19970522		
BR 9406478	A	19960102	BR 1994-6478	19940413
EP 695295	A1	19960207	EP 1994-913588	19940413
EP 695295	B1	20020306		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1121711	A	19960501	CN 1994-191867	19940413
CN 1066141	B	20010523		
HU 73558	A2	19960828	HU 1995-3040	19940413
HU 221475	B	20021028		
JP 08508723	T	19960917	JP 1994-521408	19940413
JP 3483254	B2	20040106		
RU 2140413	C1	19991027	RU 1995-120099	19940413
PL 179463	B1	20000929	PL 1994-311228	19940413
AT 214053	T	20020315	AT 1994-913588	19940413
PT 695295	T	20020830	PT 1994-913588	19940413
ES 2173916	T3	20021101	ES 1994-913588	19940413
CZ 291468	B6	20030312	CZ 1995-2768	19940413
FI 9504994	A	19951019	FI 1995-4994	19951019
FI 113650	B1	20040531		
US 5703017	A	19971230	US 1995-537843	19951019
NO 9504211	A	19951220	NO 1995-4211	19951020
NO 307087	B1	20000207		
PRIORITY APPLN. INFO.:			DE 1993-4313412	19930423
			WO 1994-EP1141	19940413

GI



AB The title compds. [I; R1 = H, succinylimidoxy, (un)substituted N-containing 5-member heterocyclic group, etc.; R2, R3 = halogen, C1-4 alkyl or alkoxy or alkylthio, etc.; R4 = (un)substituted Ph, (un)substituted naphthyl, (un)substituted heteroarom. residue, etc.; R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl, Ph, etc.; R6 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl; X = N, (un)substituted CH; Y = direct bond, O, S; Z = O, S], useful as herbicides which have reduced toxicity com. plant species, are prepared. Thus, pyrimidine derivative II (m.p. 165°; decomposition) was prepared and demonstrated 10% plant loss when applied to *Gossypium hirsutum* (i.e., cotton) at 0.125 kg/ha, vs. 35% plant loss for a control experiment using I (R1 = OH, R2 = R3 = OMe, R4 = Ph, R5 = R6 = Me, X = CH, Y = Z = O).

MSK 1



G34 = N
G35 = 6






G38 = Ph (opt. substd. by 1 or more G48)
G40 = alkyl <containing 1-4 C>
(substd. by alkoxy <containing 1-4 C>)
G41 = bond
G42 = O
G48 = halo
G49 = alkenyl <containing 3-6 C>
(opt. substd. by 1 or more G50)
G50 = halo / Ph (opt. substd. by 1 or more G51)

Patent location: claim 1
Note: substitution is restricted

L89 ANSWER 32 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 119:138791 MARPAT Full-text
 TITLE: Cyclohexenone derivatives and their use as herbicides
 and plant growth regulators
 INVENTOR(S): Kast, Juergen; Zierke, Thomas; Bratz, Matthias;
 Misslitz, Ulf; Meyer, Norbert; Landes, Andreas;
 Rademacher, Wilhelm; Westphalen, Karl Otto; Walter,
 Helmut
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4135265	A1	19930429	DE 1991-4135265	19911025
WO 9308153	A1	19930429	WO 1992-EP2226	19920926
W: AU, BR, CA, CS, HU, JP, KR, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9226482	A	19930521	AU 1992-26482	19920926
AU 662018	B2	19950817		
EP 609259	A1	19940810	EP 1992-920691	19920926
EP 609259	B1	19951122		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 07500821	T	19950126	JP 1992-507379	19920926
AT 130596	T	19951215	AT 1992-920691	19920926
ES 2081134	T3	19960216	ES 1992-920691	19920926
US 5523462	A	19960604	US 1994-211819	19940419
PRIORITY APPLN. INFO.:			DE 1991-4135265	19911025
			WO 1992-EP2226	19920926
OTHER SOURCE(S):	CASREACT 119:138791			
GI				




AB The title compds. I (R1 = alkyl, alkenyl, etc.; X, Y = alkoxy, hydroxy, amino, etc.; W = oxo or imino group) and their uses as herbicides or plant growth

10/566911

regulators are claimed. More specifically, I are 3-oxo-4-cyclohexen-1,1-dicarboxylates or 3,5-dioxocyclohexane-1,1- dicarboxylates. Treatment of di-Et 3-[(cyclopropylcarbonyl)oxy]-5-oxo-3- cyclohexene-1,1-dicarboxylate (II) with DMAP in methylene chloride gave di-Et 4-(cyclopropylcarbonyl)-3,5-dioxo-1,1-cyclohexanedicarboxylate (III).

NOTE 1



G4 = 14



G5 = 19



G8 = alkylene <containing 1-5 C>
(opt. substd. by (1-3) G12)

G9 = alkenyl <containing 2-5 C>
(opt. substd. by (1-3) G12)

G10 = O

G12 = halo / Ph (opt. substd. by (1-3) G13) / 353



G13 = halo

Derivative: and agriculturally acceptable salts and esters
Patent location: claim 1

NOTE 3

10/566911



G4 = 14



G5 = 19



G8 = alkylene <containing 1-5 C>
(opt. substd. by (1-3) G12)

G9 = alkenyl <containing 2-5 C>
(opt. substd. by (1-3) G12)

G10 = O

G12 = halo / Ph (opt. substd. by (1-3) G13) / 352



G13 = halo

Patent location: claim 2

MSIR 4



G5 = 19



G8 = alkylene <containing 1-5 C>
(opt. substd. by (1-3) G12)

G9 = alkenyl <containing 2-5 C>
(opt. substd. by (1-3) G12)

G10 = O

10/566911

G12 = halo / Ph (opt. substd. by (1-3) G13) / 303



G13 = halo

Patent location: claim 3

L89 ANSWER 33 OF 36 MARPAT COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 118:102914 MARPAT Full-text

TITLE: Metallocenes containing ligands of 2-substituted indenyl derivatives, process for their preparation, and their use as polymerization catalysts

INVENTOR(S): Winter, Andreas; Antberg, Martin; Spaleck, Walter; Rohrmann, Juergen; Dolle, Volker

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Can. Pat. Appl., 31 pp.
CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2055218	A1	19920513	CA 1991-2055218	19911108
CA 2055218	C	20020903		
ES 2090209	T3	19961016	ES 1991-118680	19911101
US 5276208	A	19940104	US 1991-789361	19911108
AU 9187760	A	19920514	AU 1991-87760	19911111
AU 640287	B2	19930819		
ZA 9108927	A	19920729	ZA 1991-8927	19911111
JP 06340684	A	19941213	JP 1991-294690	19911111
JP 3282839	B2	20020520		
US 37208	E1	20010605	US 1994-324260	19941017
US 39532	E1	20070327	US 1997-895909	19970717
US 39561	E1	20070410	US 1997-895950	19970717
US 37573	E1	20020305	US 1999-252719	19990219
PRIORITY APPLN. INFO.:			DE 1990-4035884	19901112
			US 1991-789361	19911108
			DE 1992-4225649	19920803
			US 1993-101408	19930803
			US 1994-324260	19941017

AB Olefins, especially C₃H₆, are stereospecifically polymerized using the title catalysts to give polymers with high crystallinity, hardness and m.p., useful as engineering materials. Thus, C₃H₆ was polymerized using dimethyl(2-methyl-4,5,6,7-tetrahydro-1-indenyl)zirconium dichloride and Me aluminosilane catalyst to give a polymer with isotactic index 96% and mol. weight 24,300.

MSTN 2C




G15 = O
 G22 = alkylene <containing 1-2 C, unbranched>
 (opt. substd. by 1 or more G23)
 G23 = F / alkyl (opt. substd. by 1 or more G21) /
 alkoxy <containing 1-10 C> / alkenyl (opt. substd. by aryl)
 / Me / Ph / 161



Patent location: claim 4
 Note: additional ring formation specified
 Note: substitution is restricted

MSR 3C



G15 = O
 G22 = alkylene <containing 1-2 C, unbranched>
 (opt. substd. by 1 or more G23)
 G23 = F / alkyl (opt. substd. by 1 or more G21) /
 alkoxy <containing 1-10 C> / alkenyl (opt. substd. by aryl)
 / Me / Ph / 161



Patent location: claim 4
 Note: additional ring formation specified
 Note: substitution is restricted


L89 ANSWER 34 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 117:213186 MARPAT Full-text
 TITLE: Preparation of bisindene derivative metallocenes as
 catalysts for polymerization of olefins
 INVENTOR(S): Winter, Andreas; Antberg, Martin; Spaleck, Walter;
 Rohrmann, Juergen; Dolle, Volker
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 485821	A1	19920520	EP 1991-118680	19911101
EP 485821	B1	19960612		
R: BE, DE, ES, FR, GB, IT, NL				
ES 2090209	T3	19961016	ES 1991-118680	19911101
US 5276208	A	19940104	US 1991-789361	19911108
AU 9187760	A	19920514	AU 1991-87760	19911111
AU 640287	B2	19930819		
ZA 9108927	A	19920729	ZA 1991-8927	19911111
JP 06340684	A	19941213	JP 1991-294690	19911111
JP 3282839	B2	20020520		
US 37208	E1	20010605	US 1994-324260	19941017
US 39532	E1	20070327	US 1997-895909	19970717
US 39561	E1	20070410	US 1997-895950	19970717
US 37573	E1	20020305	US 1999-252719	19990219

PRIORITY APPLN. INFO.:

DE 1990-4035884	19901112
US 1991-789361	19911108
DE 1992-4225649	19920803
US 1993-101408	19930803
US 1994-324260	19941017

AB Sandwich complexes of Group IVB, VB, or VIB metals with bisindenenes of specified structure are catalysts for polymerization of olefins with high isotacticity and mol. weight. The reaction of 2-methylindene, BuLi, and Me₂SiCl₂ in Et₂O gave 52% (dimethylsilylene)bis(2-methylindene), reaction of which with BuLi and ZrCl₄ in THF-CH₂Cl₂ gave 14% racemic complex which was hydrogenated over Pt in CH₂Cl₂ to give 60% 4,4',5,5',6,6',7,7'-octahydro derivative (I). Stirring 12 dm³ liquid C₃H₆ with 72 mmol (as Al) Me₂SiCl₂ and 0.011 mmol I at 70° for 3 h gave polypropylene with productivity 50.3 kg/g I-h, weight-average mol. weight 24,300, polydispersity 2.4, isotactic index 96%, and m.p. 150°.




G15 = O
 G22 = alkylene <containing 1-2 C, unbranched>
 (opt. substd. by 1 or more G23)
 G23 = F / alkyl (opt. substd. by 1 or more G21) /
 alkoxy <containing 1-10 C> / alkenyl (opt. substd. by aryl)
 / Me / Ph / 161



Patent location: claim 4
 Note: additional ring formation specified
 Note: substitution is restricted

MSR 3C




G15 = O
 G22 = alkylene <containing 1-2 C, unbranched>
 (opt. substd. by 1 or more G23)
 G23 = F / alkyl (opt. substd. by 1 or more G21) /
 alkoxy <containing 1-10 C> / alkenyl (opt. substd. by aryl)
 / Me / Ph / 161



Patent location: claim 4
 Note: additional ring formation specified
 Note: substitution is restricted

L89 ANSWER 35 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 117:131729 MARPAT Full-text
 TITLE: Substituted bisindenyl-metalloenes, their preparation
 and use as catalysts for the polymerization of
 olefins
 INVENTOR(S): Winter, Andreas; Antberg, Martin; Spaleck, Walter;
 Rohrmann, Juergen; Dolle, Volker
 PATENT ASSIGNEE(S): Hoechst A.-G., Germany
 SOURCE: Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 485823	A1	19920520	EP 1991-118682	19911101
EP 485823	B1	19950308		
R: BE, DE, ES, FR, GB, IT, NL				
ES 2071888	T3	19950701	ES 1991-118682	19911101
CA 2055219	A1	19920513	CA 1991-2055219	19911108
CA 2055219	C	20020806		
US 5145819	A	19920908	US 1991-790234	19911108
AU 9187757	A	19920514	AU 1991-87757	19911111
AU 641341	B2	19930916		
ZA 9108926	A	19920729	ZA 1991-8926	19911111
JP 04300887	A	19921023	JP 1991-294687	19911111
JP 3272005	B2	20020408		
US 37384	E1	20010918	US 1999-352824	19990713
PRIORITY APPLN. INFO.:			DE 1990-4035883	19901112
GI				




AB I (R1,R2 = H, organic group, halogen; R3,R4 = H, halogen, organic group optionally containing heteroatom; R5,R6 = as for R3, R4 but not H; R7 = organic or heteroatom-containing organic group; R8,R9,R10 = H, halogen, organic group; m,n = 0-2, with m + n = 0-2; M = IVb, Vb, VIb element) are obtained for use as catalysts, in conjunction with aluminoxanes, for the stereospecific polymerization of olefins. Thus, 1,2-ethenediylbis(2-methyl-1-

indene)zirconium dichloride (II) was obtained from the ligand and $ZrCl_4$ in THF. Propylene (12 dm³) was mixed with 35 cm³ PhMe containing Me aluminoxane (52 mmol Al) and to this was added 6.9 mg II and Me aluminoxane (20 mmol Al) in PhMe and the mixture was heated at 70° to give 1.56 kg isotactic polypropylene (226 kg polymer/g II). Use of metallocenes unsubstituted in the 2-position of the indene ring resulted in lower mol. weight polymers.

MSTR 2C

G19



G15 = O
 G22 = alkylene <containing 1-2 C, unbranched>
 (opt. substd. by 1 or more G23)
 G23 = F / alkyl (opt. substd. by 1 or more G21) /
 alkoxy <containing 1-10 C> / alkenyl (opt. substd. by aryl)
 / Me / Ph / 161




Patent location: claim 4
 Note: additional ring formation specified
 Note: substitution is restricted

L89 ANSWER 36 OF 36 MARPAT COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 115:49729 MARPAT Full-text
 TITLE: Preparation of substituted 2-pyrimidinyl and
 2-triazinylacetic acid derivatives
 INVENTOR(S): Harde, Christoph; Nordhoff, Erhard; Krueger, Anita;
 Krueger, Gabriele; Tarara, Gerhard; Wegner, Peter;
 Heinrich, Nikolaus; Koetter, Clemens; Johann, Gerhard;
 et al.
 PATENT ASSIGNEE(S): Schering A.-G., Germany
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 422751	A2	19910417	EP 1990-250250	19901004

10/566911

EP 422751	A3	19910925	
EP 422751	B1	19960814	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE			
DE 3934020	A1	19910418	DE 1989-3934020 19891009
US 5098465	A	19920324	US 1990-590675 19901001
AT 141264	T	19960815	AT 1990-250250 19901004
ES 2093632	T3	19970101	ES 1990-250250 19901004
JP 03169868	A	19910723	JP 1990-269690 19901009
US 5238907	A	19930824	US 1992-818518 19920109
PRIORITY APPLN. INFO.:			DE 1989-3934020 19891009
			US 1990-590675 19901001
OTHER SOURCE(S):		CASREACT 115:49729	
GI			




I



II

AB Title compds. [I; A = CO2R1, CONR6R7, cyano; R1 = H, (O- or S-interrupted) (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, dialkylmethyleimino, cycloalkyleneimino; R2,R3 = alkyl, CF3, alkoxy, alkoxyalkyl, alkylthio, alkylamino, halo; R4 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; R5 = H, R4; R4R5C = cycloalkyl; R6,R7 = H, alkyl; X = N, CH], with restrictions, were prepared. Thus, Me(CH2)3CO2Et in THF was added to (Me2CH)2NLI in THF at -60°; after 1 h 4,6-dimethoxy-2-methylsulfonylpyrimidine was added and the mixture was warmed to 10° over 2 h to give 42% title compound II. Several I at 0.3 kg/ha preemergent gave 90-100% damage on Bromus tectorum.

MSSTP 1A



G2 = alkenyloxy <containing 3-8 C>
(opt. substd. by 1 or more G8)
G8 = Ph / halo
G10 = 61

6G20-G21

G11 = 61

10/566911

$6\text{G}^{20}\text{--G}^{21}$

G12 = 7



G13 = alkyl <containing 1-10 C>
(opt. substd. by 1 or more G14)

G14 = 61 / Ph (opt. substd. by 1 or more halo)

$6\text{G}^{20}\text{--G}^{21}$

G17 = N

G20 = O

Patent location:

Note:

claim 1


alkoxy in G2 may be interrupted with oxygen or sulfur atoms

Note:

Stereochemistry:

substitution is restricted
and optically active isomers

MSTR 1B



G2 = alkenyloxy <containing 3-8 C>
(opt. substd. by 1 or more G8)

G8 = Ph / halo

G10 = 61

$6\text{G}^{20}\text{--G}^{21}$

G11 = 61

$6\text{G}^{20}\text{--G}^{21}$


10/566911

G13 = alkyl <containing 1-10 C>
(opt. substd. by 1 or more G14)
G14 = 61 / Ph (opt. substd. by 1 or more halo)

$6\text{G}^{20}-\text{G}^{21}$

G17 = N
G20 = O
Patent location: claim 1
Note: alkoxy in G2 may be interrupted with oxygen or sulfur atoms
Note: substitution is restricted
Stereochemistry: and optically active isomers

MSTR 1C



G2 = alkenyloxy <containing 3-8 C>
(opt. substd. by 1 or more G8)
G8 = Ph / halo
G10 = 61

$6\text{G}^{20}-\text{G}^{21}$

G11 = 61

$6\text{G}^{20}-\text{G}^{21}$

G13 = alkyl <containing 1-10 C>
(opt. substd. by 1 or more G14)
G14 = 61 / Ph (opt. substd. by 1 or more halo)

$6\text{G}^{20}-\text{G}^{21}$

G17 = N

10/566911

G19 = alkyl <containing 1-10 C>
(opt. substd. by 1 or more G14)

G20 = O

Patent location: claim 1

Note: alkoxy in G2 may be interrupted with oxygen or
sulfur atoms

Note: substitution is restricted

Stereochemistry: and optically active isomers

=> d his full

(FILE 'HOME' ENTERED AT 12:22:44 ON 16 APR 2008)

FILE 'REGISTRY' ENTERED AT 12:22:53 ON 16 APR 2008

L1 STRUCTURE UPLOADED
 L2 9 SEA SSS SAM L1
 D SCA

FILE 'CAPLUS' ENTERED AT 12:24:39 ON 16 APR 2008

E US2006-566911 /APPS
 L3 1 SEA ABB=ON PLU=ON US2006-566911 /AP
 D SCA
 SEL RN

FILE 'REGISTRY' ENTERED AT 12:25:57 ON 16 APR 2008

L4 211 SEA ABB=ON PLU=ON (100-02-7/BI OR 100-39-0/BI OR 107714-87-4/
 BI OR 110-87-2/BI OR 110-91-8/BI OR 1145-76-2/BI OR 126918-17-0
 /BI OR 127000-90-2/BI OR 133775-25-4/BI OR 133775-26-5/BI OR
 135206-87-0/BI OR 135270-08-5/BI OR 135272-36-5/BI OR 146500-63
 -2/BI OR 146500-65-4/BI OR 1608-24-8/BI OR 17392-83-5/BI OR
 1743-00-6/BI OR 1885-14-9/BI OR 1979-51-7/BI OR 1979-52-8/BI
 OR 1979-53-9/BI OR 1979-54-0/BI OR 207672-95-5/BI OR 210481-22-
 4/BI OR 210481-23-5/BI OR 212890-35-2/BI OR 220676-08-4/BI OR
 220676-10-8/BI OR 220676-12-0/BI OR 220676-13-1/BI OR 220676-14
 -2/BI OR 220676-15-3/BI OR 253266-68-1/BI OR 253266-69-2/BI OR
 253266-71-6/BI OR 253266-72-7/BI OR 253266-73-8/BI OR 28321-07-
 5/BI OR 28321-09-7/BI OR 286017-80-9/BI OR 288-88-0/BI OR
 348-57-2/BI OR 36029-95-5/BI OR 36029-97-7/BI OR 36029-98-8/BI
 OR 36030-01-0/BI OR 405-42-5/BI OR 492450-12-1/BI OR 51336-94-8
 /BI OR 52805-36-4/BI OR 616897-41-7/BI OR 6373-46-2/BI OR
 645-36-3/BI OR 678188-96-0/BI OR 74670-68-1/BI OR 767-00-0/BI
 OR 7785-11-7/BI OR 844877-73-2/BI OR 844877-76-5/BI OR
 844877-80-1/BI OR 844877-81-2/BI OR 844877-82-3/BI OR 844877-83
 -4/BI OR 844877-84-5/BI OR 844877-85-6/BI OR 844877-86-7/BI OR
 844877-87-8/BI OR 844877-88-9/BI OR 844877-89-0/BI OR 844877-90
 -3/BI OR 844877-91-4/BI OR 844877-92-5/BI OR 844877-93-6/BI OR
 844877-94-7/BI OR 844877-95-8/BI OR 844877-96-9/BI OR 844877-97
 -0/BI OR 844877-98-1/BI OR 844877-99-2/BI OR 844878-00-8/BI OR
 844878-01-9/BI OR 844878-02-0/BI OR 844878-03-1/BI OR 844878-04
 -2/BI OR 844878-05-3/BI OR 844878-06-4/BI OR 844878-07-5/BI OR
 844878-08-6/BI OR 844878-09-7/BI OR 844878-10-0/BI OR 844878-11
 -1/BI OR 844878-12-2/BI OR 844878-13-3/BI OR 844878-14-4/BI OR
 844878-15-5/BI OR 844878-16-6/BI OR 844878-17-7/BI OR 844878-18
 -8/BI OR 844878-19-9/BI OR 844878-20-2/BI OR 844878-21-3/BI OR
 844878

L5 1000 SEA ABB=ON PLU=ON 84487!-7/RN

L6 147 SEA ABB=ON PLU=ON L4 AND L5

L7 STRUCTURE UPLOADED

L8 9 SEA ABB=ON PLU=ON L2 AND L6

FILE 'CAPLUS' ENTERED AT 12:36:18 ON 16 APR 2008

L9 1 SEA ABB=ON PLU=ON L6

FILE 'REGISTRY' ENTERED AT 12:36:23 ON 16 APR 2008

L10 9 SEA SSS SAM L7

L11 STRUCTURE UPLOADED

L12 9 SEA SSS SAM L11

10/566911

```
L13      STRUCTURE UPLOADED
L14      11 SEA SSS SAM L13
          D SCA
          D STAT QUE L14
L15      STRUCTURE UPLOADED
L16      9 SEA SSS SAM L15
L17      127 SEA SSS FUL L15
          SAVE TEMP L17 RIC911STR15L/A

FILE 'CAPLUS' ENTERED AT 12:46:41 ON 16 APR 2008
L18      1 SEA ABB=ON PLU=ON L17

FILE 'BEILSTEIN' ENTERED AT 12:46:53 ON 16 APR 2008
L19      0 SEA SSS SAM L15
L20      0 SEA SSS FUL L15

FILE 'MARPAT' ENTERED AT 12:47:33 ON 16 APR 2008
L21      6 SEA SSS SAM L15
L22      215 SEA SSS FUL L15
          SAVE TEMP L22 RIC911MARPA
L23      214 SEA ABB=ON PLU=ON L22/COM
L24      STRUCTURE UPLOADED
L25      1 SEA SUB=L22 SSS SAM L24
          D SCA
L26      1 SEA SUB=L22 SSS FUL L24
          D SCA
L27      STRUCTURE UPLOADED
L28      12 SEA SUB=L22 SSS SAM L27
L29      STRUCTURE UPLOADED
L30      1 SEA SUB=L22 SSS SAM L29
          D SCA
L31      STRUCTURE UPLOADED
          D STAT QUE L30
L32      11 SEA SUB=L22 SSS SAM L31
          D SCA
L33      STRUCTURE UPLOADED
L34      11 SEA SUB=L22 SSS SAM L33
L35      STRUCTURE UPLOADED
L36      11 SEA SUB=L22 SSS SAM L35
L37      STRUCTURE UPLOADED
L38      7 SEA SUB=L22 SSS SAM L37
          D SCA
          D SCA
L39      STRUCTURE UPLOADED
L40      7 SEA SUB=L22 SSS SAM L39
L41      STRUCTURE UPLOADED
L42      7 SEA SUB=L22 SSS SAM L41
          D SCA
L43      STRUCTURE UPLOADED
L44      7 SEA SUB=L22 SSS SAM L43
L45      STRUCTURE UPLOADED
L46      7 SEA SUB=L22 SSS SAM L45
          D SCA
L47      99 SEA SUB=L22 SSS FUL L45
L48      STRUCTURE UPLOADED
L49      STRUCTURE UPLOADED
L50      STRUCTURE UPLOADED
L51      STRUCTURE UPLOADED
L*** DEL 7 S L45 SAM SSS SUB=L22
L*** DEL STRUCTURE UPLOADED
```

10/566911

```
L*** DEL      7 S L52 SAM SSS SUB=L22
L52           STRUCTURE UPLOADED
L53           7 SEA SUB=L22 SSS SAM L52
L54           STRUCTURE UPLOADED
L55           5 SEA SUB=L22 SSS SAM L54
L56           D SCA
L56           STRUCTURE UPLOADED
L57           STRUCTURE UPLOADED
L58           1 SEA SUB=L22 SSS SAM L57
L58           D SCA
L*** DEL      2 S L57 FULL SSS SUB=L22
L59           STRUCTURE UPLOADED
L60           4 SEA SUB=L47 SSS SAM L59
L60           D SCA
L61           23 SEA SUB=L47 SSS FUL L59
L62           22 SEA ABB=ON PLU=ON L61/COM
L63           STRUCTURE UPLOADED
L64           1 SEA SUB=L22 SSS SAM L63
L65           20 SEA SUB=L22 SSS FUL L63
L66           19 SEA ABB=ON PLU=ON L65/COM
L67           STRUCTURE UPLOADED
L68           1 SEA SUB=L22 SSS SAM L67
L68           D SCA
L69           STRUCTURE UPLOADED
L70           1 SEA SUB=L22 SSS SAM L69
L71           17 SEA SUB=L22 SSS FUL L69
L72           17 SEA ABB=ON PLU=ON L71/COM
L73           36 SEA ABB=ON PLU=ON L72 OR L62
L73           D COST

FILE 'CAPLUS' ENTERED AT 14:20:02 ON 16 APR 2008
L74           15476 SEA ABB=ON PLU=ON KIM B?/AU
L75           966 SEA ABB=ON PLU=ON MIN Y?/AU
L*** DEL      0 S LEE Y?/AU
L76           30107 SEA ABB=ON PLU=ON LEE Y?/AU
L77           1881 SEA ABB=ON PLU=ON PARK N?/AU
L78           9952 SEA ABB=ON PLU=ON KIM W?/AU
L79           1 SEA ABB=ON PLU=ON L74 AND L75 AND L76 AND L77 AND L78
L80           13 SEA ABB=ON PLU=ON L74 AND L75 AND L76 AND L77
L81           1 SEA ABB=ON PLU=ON L74 AND L75 AND L76 AND L78
L82           1 SEA ABB=ON PLU=ON L74 AND L75 AND L77 AND L78
L83           1 SEA ABB=ON PLU=ON L74 AND L76 AND L77 AND L78
L84           1 SEA ABB=ON PLU=ON L75 AND L76 AND L77 AND L78
L84           D AU L80 1-3
L85           13 SEA ABB=ON PLU=ON (L79 OR L80 OR L81 OR L82 OR L83 OR L84)
L86           1 SEA ABB=ON PLU=ON L22 AND (L74 OR L75 OR L76 OR L77 OR L78)

FILE 'REGISTRY' ENTERED AT 14:24:28 ON 16 APR 2008

FILE 'CAPLUS' ENTERED AT 14:24:31 ON 16 APR 2008
L87           D STAT QUE L85
L87           D IBIB ABS L85 1-13

FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 14:25:22 ON 16 APR 2008
L87           14 SEA ABB=ON PLU=ON L85

FILE 'CAPLUS, WPIX' ENTERED AT 14:25:36 ON 16 APR 2008
L88           15 DUP REM L85 L87 (12 DUPLICATES REMOVED)
L88           ANSWERS '1-13' FROM FILE CAPLUS
L88           ANSWERS '14-15' FROM FILE WPIX
```

D IALL L88 14-15

FILE 'REGISTRY' ENTERED AT 14:25:56 ON 16 APR 2008

FILE 'CAPLUS' ENTERED AT 14:25:59 ON 16 APR 2008
D STAT QUE L18FILE 'BEILSTEIN' ENTERED AT 14:26:07 ON 16 APR 2008
D STAT QUE L20FILE 'MARPAT' ENTERED AT 14:26:24 ON 16 APR 2008
D STAT QUE L62
D STAT QUE L72

L89 36 SEA ABB=ON PLU=ON L62 OR L72

FILE 'CAPLUS' ENTERED AT 14:27:17 ON 16 APR 2008
D IBIB ABS HITSTR L18 TOTFILE 'MARPAT' ENTERED AT 14:27:20 ON 16 APR 2008
D IBIB ABS QHIT L89 1-36

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.STRUCTURE FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8
DICTIONARY FILE UPDATES: 15 APR 2008 HIGHEST RN 1015083-77-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

FILE BEILSTEIN

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

FILE CONTAINS 10,322,368 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

```

*****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
*****

```

>>> Price change as of January 1st, 2008: Connect Time and Structure Search fees re-introduced. See NEWS and HELP COST <<<

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 148 ISS 14 (20080411/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US	20080051413	28	FEB	2008
DE	102006039038	21	FEB	2008
EP	1889831	20	FEB	2008
JP	2008044933	28	FEB	2008
WO	2008028336	13	MAR	2008
GB	2440819	13	FEB	2008
FR	2904973	22	FEB	2008
RU	2317993	27	FEB	2008
CA	2593150	06	JAN	2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT have increased from 100,000 to 200,000 for both on-line and batch searches. For more information on MARPAT search limits, type HELP SLIMITS at an arrow prompt.

FILE MEDLINE

FILE LAST UPDATED: 15 Apr 2008 (20080415/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

FILE EMBASE

FILE COVERS 1974 TO 16 Apr 2008 (20080416/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOSIS

FILE COVERS 1926 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 9 April 2008 (20080409/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current BIOSIS indexing.

FILE WPIX

FILE LAST UPDATED: 12 APR 2008 <20080412/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200824 <200824/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> IPC Reform backfile reclassification has been loaded to the end of November 2007. No update date (UP) has been created for the reclassified documents, but they can be identified by 20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC and 20071130/UPIC. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE

<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:

http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0710.p

>>> XML document distribution format now available - See HELP XMLDOC <<<

>>> ECLA Codes and Current US National Classifications have been added -
see NEWS and HELP CHANGE <<<

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Updated PDF files in the following links:

http://www.stn-international.de/stndatabases/details/ico_0803.zip

http://www.stn-international.de/stndatabases/details/epc_0803.zip

Supplement of all changed ECLA items:

http://www.stn-international.de/stndatabases/details/ecla_0803s.zip <<

=>